Gary Remington - Publications

Affiliations: 
University of Toronto, Toronto, ON, Canada 
Area:
Pharmacology, Mental Health, Epidemiology

458 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Stogios N, Smith E, Bowden S, Tran V, Asgariroozbehani R, McIntyre WB, Remington G, Siskind D, Agarwal SM, Hahn MK. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 34446830 DOI: 10.1038/s41386-021-01163-7  1
2021 Remington G, Hahn MK, Agarwal SM, Chintoh A, Agid O. Schizophrenia: Antipsychotics and Drug Development. Behavioural Brain Research. 113507. PMID 34352293 DOI: 10.1016/j.bbr.2021.113507  1
2021 Krzyzanowski D, Agid O, Goghari V, Remington G. Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia. Schizophrenia Research. Cognition. 26: 100205. PMID 34258238 DOI: 10.1016/j.scog.2021.100205  1
2021 Iwata Y, Nakajima S, Plitman E, Truong P, Bani-Fatemi A, Caravaggio F, Kim J, Shah P, Mar W, Chavez S, Remington G, Gerretsen P, De Luca V, Sailasuta N, Graff-Guerrero A. Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia. Schizophrenia Bulletin Open. 2: sgab006. PMID 33969302 DOI: 10.1093/schizbullopen/sgab006  1
2021 Stogios N, Gdanski A, Gerretsen P, Chintoh AF, Graff-Guerrero A, Rajji TK, Remington G, Hahn MK, Agarwal SM. Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. Npj Schizophrenia. 7: 22. PMID 33903594 DOI: 10.1038/s41537-021-00151-6  1
2021 Agarwal SM, Panda R, Costa-Dookhan KA, MacKenzie NE, Treen QC, Caravaggio F, Hashim E, Leung G, Kirpalani A, Matheson K, Chintoh AF, Kramer CK, Voineskos AN, Graff-Guerrero A, Remington GJ, et al. Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. Translational Psychiatry. 11: 219. PMID 33854039 DOI: 10.1038/s41398-021-01338-2  1
2021 Kanagasundaram P, Lee J, Prasad F, Costa-Dookhan KA, Hamel L, Gordon M, Remington G, Hahn MK, Agarwal SM. Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis. Frontiers in Psychiatry. 12: 642403. PMID 33815174 DOI: 10.3389/fpsyt.2021.642403  1
2021 Takeuchi H, Leucht S, Kane JM, Agid O, Remington G. Antipsychotic Medications: Enhancing Use to Improve Outcomes. Schizophrenia Bulletin. PMID 33748864 DOI: 10.1093/schbul/sbab016  1
2021 Costa-Dookhan KA, Rajji TK, Tran VN, Bowden S, Mueller DJ, Remington GJ, Agarwal SM, Hahn MK. Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia. Scientific Reports. 11: 2004. PMID 33479273 DOI: 10.1038/s41598-021-81493-0  1
2021 Caravaggio F, Porco N, Kim J, Torres-Carmona E, Brown E, Iwata Y, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Measuring amphetamine-induced dopamine release in humans: A comparative meta-analysis of [ C]-raclopride and [ C]-(+)-PHNO studies. Synapse (New York, N.Y.). e22195. PMID 33471400 DOI: 10.1002/syn.22195  1
2020 Grimes KM, Foussias G, Remington G, Kalahani-Bargis K, Zakzanis KK. Stability of Verbal Fluency in Outpatients with Schizophrenia. Psychiatry Research. 113528. PMID 33189369 DOI: 10.1016/j.psychres.2020.113528  1
2020 Daniell K, Kim J, Iwata Y, Caravaggio F, Brown E, Remington G, Agid O, Graff-Guerrero A, Gerretsen P. Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophrenia. Journal of Psychiatric Research. PMID 33168197 DOI: 10.1016/j.jpsychires.2020.10.016  1
2020 Islam F, Maciukiewicz M, Freeman N, Huang E, Tiwari A, Mulsant BH, Pollock BG, Remington G, Kennedy JL, Müller DJ, Rajji TK. Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia. Journal of Psychopharmacology (Oxford, England). 269881120946288. PMID 33143542 DOI: 10.1177/0269881120946288  1
2020 Lu JY, Tiwari AK, Freeman N, Zai GC, Luca V, Müller DJ, Tampakeras M, Herbert D, Emmerson H, Cheema SY, King N, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, ... Remington G, et al. Liver enzyme gene and tardive dyskinesia. Pharmacogenomics. PMID 32969762 DOI: 10.2217/pgs-2020-0065  1
2020 Takeuchi H, Borlido C, Sanches M, Teo C, Harber L, Agid O, Remington G. Adherence to Clozapine vs. Other Antipsychotics in Schizophrenia. Acta Psychiatrica Scandinavica. PMID 32627168 DOI: 10.1111/Acps.13208  1
2020 Remington G, Powell V. Clozapine and COVID-19. Journal of Psychiatry & Neuroscience : Jpn. 45: E1. PMID 32584527 DOI: 10.1503/Jpn.2045301  1
2020 Remington G, Kapur S. Antipsychotics Circa 2020: What Are We Thinking? Neuropharmacology. 108181. PMID 32533978 DOI: 10.1016/j.neuropharm.2020.108181  1
2020 Takeuchi H, Remington G. Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. Journal of Psychopharmacology (Oxford, England). 269881120922964. PMID 32448023 DOI: 10.1177/0269881120922964  1
2020 Takeuchi H, MacKenzie NE, Samaroo D, Agid O, Remington G, Leucht S. Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. Schizophrenia Bulletin. PMID 32415847 DOI: 10.1093/Schbul/Sbaa063  1
2020 Maes MS, Lu JY, Tiwari AK, Freeman N, de Luca V, Müller DJ, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL, Zai CC. Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia. Drug Development Research. PMID 32394511 DOI: 10.1002/Ddr.21681  1
2020 Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H. Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis. Cns Drugs. PMID 32219681 DOI: 10.1007/S40263-020-00713-9  1
2020 Shah P, Plitman E, Iwata Y, Kim J, Nakajima S, Chan N, Brown EE, Caravaggio F, Torres E, Hahn M, Chakravarty MM, Remington G, Gerretsen P, Graff-Guerrero A. Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. Journal of Psychiatric Research. 124: 151-158. PMID 32169688 DOI: 10.1016/J.Jpsychires.2020.02.032  1
2020 Zipursky RB, Odejayi G, Agid O, Remington G. You say "schizophrenia" and I say "psychosis": Just tell me when I can come off this medication. Schizophrenia Research. PMID 32115315 DOI: 10.1016/J.Schres.2020.02.009  1
2020 Berkhout S, Zaheer J, Remington G. M246. Digital Self-Monitoring And Embodiment In First Episode Psychosis: Ethical Considerations Schizophrenia Bulletin. 46. DOI: 10.1093/Schbul/Sbaa030.558  0.01
2020 Lee J, Yee JY, See YM, Tang C, Ng BT, Chowbay B, Remington G. M215. Factors Associated With Clozapine Response And Resistance In Schizophrenia Schizophrenia Bulletin. 46. DOI: 10.1093/Schbul/Sbaa030.527  1
2020 Stogios N, Agarwal SM, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, Cohn T, Taylor V, Remington G, Faulkner G, Hahn M. A Systematic Review and Meta-Analysis of Pharmacological Interventions for Reduction of Weight Gain in People With Schizophrenia: 2019 Update Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.915  1
2020 Kim J, Iwata Y, Plitman E, Caravaggio F, Shah P, Luca VD, Remington G, Graff-Guerrero A, Gerretsen P. Improving Insight in Non-Treatment-Resistant Patients With Schizophrenia With Transcranial Direct Current Stimulation Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.488  1
2020 Islam F, Maciukiewicz M, Freeman N, Huang E, Tiwari AK, Mulsant BH, Pollock BG, Remington G, Kennedy JL, Rajji TK, Mueller DJ. Contributions of Cholinergic Receptor Muscarinic 1 (CHRM1) and CYP1A2 Gene Variants on the Effects of Plasma Ratio of Clozapine/N-Desmethylclozapine on Working Memory in Schizophrenia Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.415  1
2020 Hahn M, Agarwal SM, Costa-Dookhan K, Roshni P, Nicole M, Cauccio-Treen Q, Caravaggio F, Hashim E, Kirpalani A, Chintoh A, Kramer C, Voineskos A, Graff-Guerrero A, Remington G. Metformin for Early Onset Comorbid Type 2 Diabetes or Prediabetes in Schizophrenia Spectrum Disorders: A Double-Blind Randomized Pilot Study Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.1057  1
2020 Costa-Dookhan K, Agarwal SM, Chintoh A, MacKenzie N, Leavitt D, Treen QC, Remington G, Ward K, Hahn M. Investigating Metabolic Dysfunction and Metabolomic Profile Changes in Antipsychotic Naive Patients Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.1041  1
2019 Zai CC, Tiwari AK, Zai GC, Freeman N, Pouget JG, Greco J, Tampakeras M, Shaikh SA, Herbert D, Emmerson H, Cheema SY, Braganza N, Müller DJ, Voineskos AN, Remington G, et al. Association Study of the Complement Component C4 Gene in Tardive Dyskinesia. Frontiers in Pharmacology. 10: 1339. PMID 31849639 DOI: 10.3389/Fphar.2019.01339  1
2019 Kim J, Plitman E, Iwata Y, Nakajima S, Mar W, Patel R, Chavez S, Chung JK, Caravaggio F, Chakravarty MM, Remington G, Gerretsen P, Graff-Guerrero A. Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 109839. PMID 31843627 DOI: 10.1016/J.Pnpbp.2019.109839  1
2019 Tarumi R, Tsugawa S, Noda Y, Plitman E, Honda S, Matsushita K, Chavez S, Sawada K, Wada M, Matsui M, Fujii S, Miyazaki T, Chakravarty MM, Uchida H, Remington G, et al. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 31842203 DOI: 10.1038/S41386-019-0589-Z  1
2019 Puveendrakumaran P, Fervaha G, Caravaggio F, Remington G. Assessing analytic and intuitive reasoning using the cognitive reflection test in young patients with schizophrenia. Psychiatry Research. 112683. PMID 31818543 DOI: 10.1016/J.Psychres.2019.112683  1
2019 Costa-Dookhan KA, Agarwal SM, Chintoh A, Tran VN, Stogios N, Ebdrup BH, Sockalingam S, Rajji TK, Remington GJ, Siskind D, Hahn MK. The clozapine to norclozapine ratio: A narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opinion On Drug Safety. PMID 31770500 DOI: 10.1080/14740338.2020.1698545  1
2019 Shah P, Iwata Y, Brown EE, Kim J, Sanches M, Takeuchi H, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. European Archives of Psychiatry and Clinical Neuroscience. PMID 31428862 DOI: 10.1007/S00406-019-01053-6  1
2019 Pardis P, Remington G, Panda R, Lemez M, Agid O. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review. Journal of Psychopharmacology (Oxford, England). 269881119862535. PMID 31347436 DOI: 10.1177/0269881119862535  1
2019 Kim J, Plitman E, Nakajima S, Alshehri Y, Iwata Y, Chung JK, Caravaggio F, Menon M, Blumberger DM, Pollock BG, Remington G, De Luca V, Graff-Guerrero A, Gerretsen P. Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia. European Psychiatry : the Journal of the Association of European Psychiatrists. 61: 63-71. PMID 31326732 DOI: 10.1016/J.Eurpsy.2019.06.007  1
2019 Noël MC, Powell V, Burton L, Panda R, Remington G. Clozapine-Related Myocarditis and Rechallenge: A Case Series and Clinical Review. Journal of Clinical Psychopharmacology. PMID 31205188 DOI: 10.1097/JCP.0000000000001062  1
2019 Alkelai A, Greenbaum L, Heinzen EL, Baugh EH, Teitelbaum A, Zhu X, Strous RD, Tatarskyy P, Zai CC, Tiwari AK, Tampakeras M, Freeman N, Müller DJ, Voineskos AN, Lieberman JA, ... ... Remington G, et al. New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 109659. PMID 31153890 DOI: 10.1016/J.Pnpbp.2019.109659  1
2019 Berkhout SG, Zaheer J, Remington G. Identity, Subjectivity, and Disorders of Self in Psychosis. Culture, Medicine and Psychiatry. PMID 30980233 DOI: 10.1007/S11013-019-09631-Y  0.01
2019 Caravaggio F, Iwata Y, Kim J, Shah P, Gerretsen P, Remington G, Graff-Guerrero A. What proportion of striatal D2 receptors are occupied by endogenous dopamine at baseline? A meta-analysis with implications for understanding antipsychotic occupancy. Neuropharmacology. PMID 30940535 DOI: 10.1016/J.Neuropharm.2019.03.034  1
2019 McIntyre RS, Remington G, Correll CU, Weber R, Farahmand K, Lundt L, Burke J, Siegert S. 67 Effects of Long-term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder. Cns Spectrums. 24: 210-211. PMID 30859987 DOI: 10.1017/S109285291900052X  1
2019 Song J, Borlido C, De Luca V, Burton L, Remington G. Patient versus rater evaluation of symptom severity in treatment resistant schizophrenia receiving clozapine. Psychiatry Research. 274: 409-413. PMID 30852435 DOI: 10.1016/J.Psychres.2019.02.050  1
2019 Ricciardi L, Pringsheim T, Barnes TRE, Martino D, Gardner D, Remington G, Addington D, Morgante F, Poole N, Carson A, Edwards M. Treatment Recommendations for Tardive Dyskinesia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 706743719828968. PMID 30791698 DOI: 10.1177/0706743719828968  0.01
2019 Shah P, Iwata Y, Caravaggio F, Plitman E, Brown EE, Kim J, Chan N, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. Schizophrenia Research. PMID 30685395 DOI: 10.1016/j.schres.2019.01.005  1
2019 Luca VD, Daniela SS, Borlido C, Powell V, Leah B, Roshni P, Remington G. S109. Admixture Analysis To Model Clozapine Pharmacokinetics: Comparison Of Two Hospital-Based Samples Schizophrenia Bulletin. 45. DOI: 10.1093/Schbul/Sbz020.654  1
2019 Zai C, Tiwari A, Cheema S, Luca Vd, Mueller D, Herbert D, Shahmirian A, Freeman N, Braganza N, Voineskos A, Potkin S, Lieberman J, Meltzer H, Remington G, Kennedy JL. F103New Genetic Findings In Tardive Dyskinesia: From Cyp2D6 To C4 European Neuropsychopharmacology. 29. DOI: 10.1016/J.Euroneuro.2018.08.183  1
2019 Shah P, Iwata Y, Brown E, Caravaggio F, Kim J, Sanches M, Takeuchi H, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. S185. Treatment Response Trajectories in Treatment-Resistant Schizophrenia: A Chart Review Study Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.936  1
2019 Carmona ET, Iwata Y, Nakajima S, Plitman E, Caravaggio F, Brown E, Kim J, Shah P, Mar W, Chavez S, Remington G, Gerretsen P, Graff-Guerrero A. S167. Increased N-Acetylaspartate and Myo-Inositol Levels in Clozapine-Responders and Clozapine-Resistant Patients With Schizophrenia Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.918  1
2019 Kim J, Iwata Y, Plitman E, Caravaggio F, Shah P, Luca VD, Remington G, Graff-Guerrero A, Gerretsen P. F182. Improving Insight into Psychosis With Transcranial Direct Current Stimulation in Schizophrenia Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.719  1
2019 Kowalchuk C, Castellani L, Teo C, Kanagasundaram P, McIntyre WB, Remington G, Giacca A, Hahn M. 52. Antipsychotics Perturb Glucose Homeostasis by Inhibiting Hypothalamic KATP Channel Activation Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.066  1
2019 Agarwal SM, Ahsan ZA, Lockwood JT, Duncan MJ, Takeuchi H, Cohn T, Taylor VH, Remington G, Faulkner GEJ, Hahn M. Pharmacological interventions for prevention of weight gain in people with schizophrenia Cochrane Database of Systematic Reviews. 2019. DOI: 10.1002/14651858.Cd013337  1
2018 Kim J, Iwata Y, Plitman E, Caravaggio F, Chung JK, Shah P, Blumberger DM, Pollock BG, Remington G, Graff-Guerrero A, Gerretsen P. A meta-analysis of transcranial direct current stimulation for schizophrenia: "Is more better?" Journal of Psychiatric Research. 110: 117-126. PMID 30639917 DOI: 10.1016/J.Jpsychires.2018.12.009  1
2018 MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, Chintoh A, Remington GJ, Taylor VH, Müeller DJ, Graff-Guerrero A, Hahn MK. Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. Frontiers in Psychiatry. 9: 622. PMID 30568606 DOI: 10.3389/Fpsyt.2018.00622  1
2018 Duncan MJ, Arbour-Nicitopoulos K, Subramaniapillai M, Remington G, Faulkner G. Revisiting the International Physical Activity Questionnaire (IPAQ): Assessing sitting time among individuals with schizophrenia. Psychiatry Research. 271: 311-318. PMID 30529312 DOI: 10.1016/J.Psychres.2018.11.063  1
2018 Takeuchi H, Siu C, Remington G, Fervaha G, Zipursky RB, Foussias G, Agid O. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30514883 DOI: 10.1038/S41386-018-0278-3  1
2018 Neufeld NH, Remington G. Clozapine-induced myocarditis in Canada: Evidence from spontaneous reports. Schizophrenia Research. PMID 30514645 DOI: 10.1016/j.schres.2018.11.015  0.01
2018 Siddiqui I, Saperia S, Fervaha G, Da Silva S, Jeffay E, Zakzanis KK, Agid O, Remington G, Foussias G. Goal-directed planning and action impairments in schizophrenia evaluated in a virtual environment. Schizophrenia Research. PMID 30471980 DOI: 10.1016/J.Schres.2018.10.012  1
2018 Saperia S, Da Silva S, Siddiqui I, Agid O, Daskalakis ZJ, Ravindran A, Voineskos AN, Zakzanis KK, Remington G, Foussias G. Reward-driven decision-making impairments in schizophrenia. Schizophrenia Research. PMID 30442476 DOI: 10.1016/J.Schres.2018.11.004  1
2018 Iwata Y, Nakajima S, Plitman E, Caravaggio F, Kim J, Shah P, Mar W, Chavez S, De Luca V, Mimura M, Remington G, Gerretsen P, Graff-Guerrero A. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. Biological Psychiatry. PMID 30389132 DOI: 10.1016/j.biopsych.2018.09.009  1
2018 Zai CC, Lee FH, Tiwari AK, Lu JY, de Luca V, Maes MS, Herbert D, Shahmirian A, Cheema SY, Zai GC, Atukuri A, Sherman M, Shaikh SA, Tampakeras M, Freeman N, ... ... Remington G, et al. Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis. Frontiers in Pharmacology. 9: 974. PMID 30283332 DOI: 10.3389/Fphar.2018.00974  1
2018 Castellani LN, Wilkin J, Abela A, Benarroch L, Ahasan Z, Teo C, Wilson V, Kowalchuk C, Giacca A, Remington GJ, Hahn MK. Effects of acute olanzapine exposure on central insulin-mediated regulation of whole body fuel selection and feeding. Psychoneuroendocrinology. 98: 127-130. PMID 30142549 DOI: 10.1016/J.Psyneuen.2018.07.028  1
2018 Lu JY, Tiwari AK, Zai GC, Rastogi A, Shaikh SA, Mueller DJ, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Wong AHC, Kennedy JL, Zai CC. Association study of Disrupted-In-Schizophrenia-1 Gene variants and Tardive Dyskinesia. Neuroscience Letters. PMID 30118782 DOI: 10.1016/J.Neulet.2018.08.007  1
2018 Shah P, Iwata Y, Plitman E, Brown EE, Caravaggio F, Kim J, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. Psychiatry Research. 268: 114-122. PMID 30015109 DOI: 10.1016/j.psychres.2018.06.070  1
2018 Siddiqui I, Remington G, Fervaha G, Fletcher PJ, Voineskos AN, Saperia S, Zakzanis KK, Foussias G. Objective investigation of activity preference in schizophrenia: A pilot study. Psychiatry Research. 267: 551-559. PMID 29980136 DOI: 10.1016/J.Psychres.2018.05.039  1
2018 Kowalchuk C, Castellani L, Chintoh A, Remington G, Giacca A, Hahn M. Antipsychotics and glucose metabolism: how brain and body collide. American Journal of Physiology. Endocrinology and Metabolism. PMID 29969315 DOI: 10.1152/Ajpendo.00164.2018  1
2018 Caravaggio F, Scifo E, Sibille EL, Hernandez-Da Mota SE, Gerretsen P, Remington G, Graff-Guerrero A. Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry. Experimental Eye Research. PMID 29883636 DOI: 10.1016/J.Exer.2018.06.006  1
2018 Rao N, Northoff G, Tagore A, Rusjan P, Kenk M, Wilson A, Houle S, Strafella A, Remington G, Mizrahi R. Impaired Prefrontal Cortical Dopamine Release in Schizophrenia During a Cognitive Task: A [11C]FLB 457 Positron Emission Tomography Study. Schizophrenia Bulletin. PMID 29878197 DOI: 10.1093/schbul/sby076  1
2018 Da Silva S, Apatsidou A, Saperia S, Siddiqui I, Jeffay E, Voineskos AN, Daskalakis ZJ, Remington G, Zakzanis KK, Foussias G. An Examination of the Multi-Faceted Motivation System in Healthy Young Adults. Frontiers in Psychiatry. 9: 191. PMID 29867611 DOI: 10.3389/Fpsyt.2018.00191  1
2018 Hafizi S, Da Silva T, Meyer JH, Kiang M, Houle S, Remington G, Prce I, Wilson AA, Rusjan PM, Sailasuta N, Mizrahi R. Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 29748630 DOI: 10.1038/S41386-018-0061-5  1
2018 Zipursky RB, Agid O, Remington G. Improving outcomes in schizophrenia by preventing early relapses. The Lancet. Psychiatry. 5: 384-386. PMID 29699735 DOI: 10.1016/S2215-0366(18)30124-X  1
2018 Pringsheim T, Gardner D, Addington D, Martino D, Morgante F, Ricciardi L, Poole N, Remington G, Edwards M, Carson A, Barnes TRE. The Assessment and Treatment of Antipsychotic-Induced Akathisia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 706743718760288. PMID 29685069 DOI: 10.1177/0706743718760288  0.01
2018 Hasnain M, Rudnick A, Bonnell WS, Remington G, Lam RW. Use of Placebo in Clinical Trials of Psychotropic Medication. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 63: 338-341. PMID 29668328 DOI: 10.1177/0706743717752917  0.01
2018 Remington G. Book Review: The Schizophrenia Spectrum The Schizophrenia Spectrum . Spaulding W. D. Silverstein S. M. Menditto A. A. , ISBN: 978-0-88937-504-8 . Pages: 94 . Format: softcover. Price: Can $34.80 . Pub Year: 2017 . Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 63: 257. PMID 29630855 DOI: 10.1177/0706743718758042  0.01
2018 Iwata Y, Nakajima S, Plitman E, Mihashi Y, Caravaggio F, Chung JK, Kim J, Gerretsen P, Mimura M, Remington G, Graff-Guerrero A. Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: A systematic review and meta-analysis ofH-MRS studies. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 29580804 DOI: 10.1016/J.Pnpbp.2018.03.016  1
2018 Takeuchi H, Fathi A, Thiyanavadivel S, Agid O, Remington G. Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled Trials. The Journal of Clinical Psychiatry. 79. PMID 29570965 DOI: 10.4088/Jcp.17R11489  1
2018 Zai CC, Maes MS, Tiwari AK, Zai GC, Remington G, Kennedy JL. Genetics of tardive dyskinesia: Promising leads and ways forward. Journal of the Neurological Sciences. PMID 29502799 DOI: 10.1016/J.Jns.2018.02.011  1
2018 Caravaggio F, Fervaha G, Browne CJ, Gerretsen P, Remington G, Graff-Guerrero A. Reward motivation in humans and its relationship to dopamine Dreceptor availability: A pilot study with dual [C]-raclopride and [C]-(+)-PHNO imaging. Journal of Psychopharmacology (Oxford, England). 269881118756059. PMID 29442593 DOI: 10.1177/0269881118756059  1
2018 Plitman E, Chavez S, Nakajima S, Iwata Y, Chung JK, Caravaggio F, Kim J, Alshehri Y, Chakravarty MM, De Luca V, Remington G, Gerretsen P, Graff-Guerrero A. Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study. Psychiatry Research. 273: 16-24. PMID 29414127 DOI: 10.1016/J.Pscychresns.2018.01.004  1
2018 Silva SD, Saperia S, Siddiqui I, Agid O, Voineskos A, Daskalakis J, Ravindran A, Zakzanis K, Remington G, Foussias G. F255. Motivation System Impairment Profiles in Schizophrenia and Major Depressive Disorder Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.869  1
2018 Iwata Y, Nakajima S, Plitman E, Chung JK, Caravaggio F, Kim J, Brown E, Shah P, Chan N, Gerretsen P, Mimura M, Chavez S, Remington G, Graff-Guerrero A. F230. Glutamatergic Neurometabolite Levels in Patients With Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton MRS Study Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.844  1
2018 Saperia S, Silva SD, Siddiqui I, Agid O, Daskalakis J, Ravindran A, Voineskos A, Zakzanis K, Remington G, Foussias G. S187. Hedonic Deficits in Schizophrenia and Major Depressive Disorder Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.1079  1
2017 Caravaggio F, Iwata Y, Plitman E, Chavez S, Borlido C, Chung JK, Kim J, Agarwal SM, Gerretsen P, Remington G, Hahn M, Graff-Guerrero A. Reduced insulin sensitivity may be related to less striatal glutamate: An 1H-MRS study in healthy non-obese humans. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 29269206 DOI: 10.1016/J.Euroneuro.2017.12.002  1
2017 Saperia S, Da Silva S, Siddiqui I, McDonald K, Agid O, Remington G, Foussias G. Investigating the predictors of happiness, life satisfaction and success in schizophrenia. Comprehensive Psychiatry. 81: 42-47. PMID 29245017 DOI: 10.1016/J.Comppsych.2017.11.005  1
2017 Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, Liang GS, O'Brien CF. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. The Journal of Clinical Psychiatry. PMID 29141124 DOI: 10.4088/JCP.17m11777  0.01
2017 Caravaggio F, Fervaha G, Iwata Y, Plitman E, Chung JK, Nakajima S, Mar W, Gerretsen P, Kim J, Chakravarty MM, Mulsant B, Pollock B, Mamo D, Remington G, Graff-Guerrero A. Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia. International Journal of Geriatric Psychiatry. PMID 29110353 DOI: 10.1002/Gps.4818  1
2017 Kowalchuk C, Teo C, Wilson V, Chintoh A, Lam L, Agarwal SM, Giacca A, Remington GJ, Hahn MK. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. Journal of Psychiatry & Neuroscience : Jpn. 42: 424-431. PMID 29083297 DOI: 10.1503/jpn.170092  0.4
2017 Caravaggio F, Fervaha G, Menon M, Remington G, Graff-Guerrero A, Gerretsen P. The neural correlates of apathy in schizophrenia: an exploratory investigation. Neuropsychologia. PMID 29079398 DOI: 10.1016/J.Neuropsychologia.2017.10.027  1
2017 Kowalchuk C, Teo C, Wilson V, Chintoh A, Lam L, Agarwal SM, Giacca A, Remington GJ, Hahn MK. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. Journal of Psychiatry & Neuroscience : Jpn. 42: 170092. PMID 29035174 DOI: 10.1503/Jpn.170092  1
2017 Siddiqui I, Remington G, Fletcher PJ, Voineskos AN, Fong JW, Saperia S, Fervaha G, Da Silva S, Zakzanis KK, Foussias G. Objective assessment of exploratory behaviour in schizophrenia using wireless motion capture. Schizophrenia Research. PMID 28954705 DOI: 10.1016/J.Schres.2017.09.011  1
2017 Takeuchi H, Thiyanavadivel S, Agid O, Remington G. Rapid vs. slow antipsychotic initiation in schizophrenia: A systematic review and meta-analysis. Schizophrenia Research. PMID 28844639 DOI: 10.1016/J.Schres.2017.08.012  1
2017 Caravaggio F, Plitman E, Chung JK, Gerretsen P, Kim J, Iwata Y, Chakravarty M, Remington G, Graff-Guerrero A. Trait impulsiveness is related to smaller post-commissural putamen volumes in males but not females. The European Journal of Neuroscience. PMID 28833754 DOI: 10.1111/Ejn.13661  1
2017 Di Ciano P, Cormick PM, Stefan C, Wong E, Kim A, Remington G, Le Foll B. The effects of buspirone on occupancy of dopamine receptors and the rat gambling task. Psychopharmacology. PMID 28825117 DOI: 10.1007/S00213-017-4715-5  1
2017 Arbour-Nicitopoulos KP, Duncan MJ, Remington G, Cairney J, Faulkner GE. The Utility of the Health Action Process Approach Model for Predicting Physical Activity Intentions and Behavior in Schizophrenia. Frontiers in Psychiatry. 8: 135. PMID 28824466 DOI: 10.3389/Fpsyt.2017.00135  1
2017 Caravaggio F, Ku Chung J, Plitman E, Boileau I, Gerretsen P, Kim J, Iwata Y, Patel R, Chakravarty MM, Remington G, Graff-Guerrero A. The relationship between subcortical brain volume and striatal dopamine D2/3 receptor availability in healthy humans assessed with [(11) C]-raclopride and [(11) C]-(+)-PHNO PET. Human Brain Mapping. PMID 28752565 DOI: 10.1002/Hbm.23744  1
2017 Freudenreich O, Remington G. Valbenazine for Tardive Dyskinesia. Clinical Schizophrenia & Related Psychoses. 11: 113-119. PMID 28742396 DOI: 10.3371/CSRP.OFGR.071717  0.01
2017 Addington J, Addington D, Abidi S, Raedler T, Remington G. CPA Treatment Guidelines for Individuals at Clinical High Risk of Psychosis. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 706743717719895. PMID 28730848 DOI: 10.1177/0706743717719895  1
2017 Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 706743717720448. PMID 28703015 DOI: 10.1177/0706743717720448  1
2017 Takeuchi H, Kantor N, Sanches M, Fervaha G, Agid O, Remington G. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. The British Journal of Psychiatry : the Journal of Mental Science. PMID 28522434 DOI: 10.1192/Bjp.Bp.116.186007  1
2017 Rabin RA, Kozak K, Zakzanis KK, Remington G, Stefan C, Budney AJ, George TP. A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls. Schizophrenia Research. PMID 28506704 DOI: 10.1016/J.Schres.2017.05.006  1
2017 Da Silva S, Saperia S, Siddiqui I, Fervaha G, Agid O, Daskalakis ZJ, Ravindran A, Voineskos AN, Zakzanis KK, Remington G, Foussias G. Investigating consummatory and anticipatory pleasure across motivation deficits in schizophrenia and healthy controls. Psychiatry Research. 254: 112-117. PMID 28460280 DOI: 10.1016/J.Psychres.2017.04.040  1
2017 Miksys S, Wadji FB, Tolledo EC, Remington G, Nobrega JN, Tyndale RF. Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28454738 DOI: 10.1016/J.Pnpbp.2017.04.030  1
2017 Koga A, Bani-Fatemi A, Hettige N, Borlido C, Zai C, Strauss J, Gerretsen P, Graff A, Remington G, De Luca V. GWAS analysis of treatment resistant schizophrenia: interaction effect of childhood trauma. Pharmacogenomics. PMID 28453389 DOI: 10.2217/Pgs-2016-0137  1
2017 Rabin RA, Barr MS, Goodman MS, Herman Y, Zakzanis KK, Kish SJ, Kiang M, Remington G, George TP. Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia versus Non-Psychiatric Controls. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28443616 DOI: 10.1038/Npp.2017.85  1
2017 Caravaggio F, Gerretsen P, Mar W, Chung JK, Plitman E, Nakajima S, Kim J, Iwata Y, Patel R, Chakravarty MM, Remington G, Graff-Guerrero A, Menon M. Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning. Psychoneuroendocrinology. 81: 80-87. PMID 28431278 DOI: 10.1016/J.Psyneuen.2017.03.020  1
2017 Zai CC, Tiwari AK, Chowdhury NI, Yilmaz Z, de Luca V, Müller DJ, Potkin SG, Lieberman JA, Meltzer HY, Voineskos AN, Remington G, Kennedy JL. Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 1-5. PMID 28394697 DOI: 10.1080/15622975.2017.1301681  1
2017 Rabin RA, Kozak K, Zakzanis KK, Remington G, George TP. Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophrenia Research. PMID 28285022 DOI: 10.1016/J.Schres.2017.03.010  1
2017 Taylor DL, Tiwari AK, Lieberman JA, Potkin SG, Meltzer HY, Knight J, Remington G, Müller DJ, Kennedy JL. Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine. Molecular Neuropsychiatry. 2: 185-197. PMID 28277565 DOI: 10.1159/000449224  1
2017 Takeuchi H, Thiyanavadivel S, Agid O, Remington G. Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. Schizophrenia Research. PMID 28242107 DOI: 10.1016/j.schres.2017.02.011  1
2017 Takeuchi H, Lee J, Fervaha G, Foussias G, Agid O, Remington G. Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation: A Pilot, Double-Blind, Randomized Controlled Trial. The Journal of Clinical Psychiatry. 78: 223-228. PMID 28234436 DOI: 10.4088/Jcp.15M10286  1
2017 Fervaha G, Takeuchi H, Foussias G, Hahn MK, Agid O, Remington G. Achievement motivation in early schizophrenia: Relationship with symptoms, cognition and functional outcome. Early Intervention in Psychiatry. PMID 28230315 DOI: 10.1111/Eip.12405  1
2017 Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G, Graff-Guerrero A. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bulletin. PMID 28187219 DOI: 10.1093/Schbul/Sbw221  1
2017 Lim MW, Remington G, Lee J. Personal Recovery in Serious Mental Illness: Making Sense of the Concept. Annals of the Academy of Medicine, Singapore. 46: 29-31. PMID 28182815  1
2017 Harber L, Takeuchi H, Borlido C, Hamidian R, Remington G. Factors associated with drug attitude in patients with schizophrenia spectrum disorders. Schizophrenia Research. PMID 28131597 DOI: 10.1016/j.schres.2017.01.033  1
2017 Takeuchi H, Thiyanavadivel S, Fervaha G, Remington G. Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review. Journal of Clinical Psychopharmacology. PMID 28129314 DOI: 10.1097/Jcp.0000000000000662  1
2017 Lanning R, Lett TA, Tiwari AK, Brandl EJ, de Luca V, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Müller DJ, Remington G, Kennedy JL, Zai CC. Association study between the neurexin-1 gene and tardive dyskinesia. Human Psychopharmacology. 32. PMID 28120489 DOI: 10.1002/Hup.2568  1
2017 Egerton A, Howes OD, Houle S, McKenzie K, Valmaggia LR, Bagby MR, Tseng HH, Bloomfield MA, Kenk M, Bhattacharyya S, Suridjan I, Chaddock CA, Winton-Brown TT, Allen P, Rusjan P, ... Remington G, et al. Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. Schizophrenia Bulletin. PMID 28057720 DOI: 10.1093/Schbul/Sbw181  1
2017 Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis. Schizophrenia Bulletin. PMID 28044008 DOI: 10.1093/Schbul/Sbw171  1
2017 Nakajima S, Iwata Y, Plitman E, Chung JK, Gerretsen P, Mar W, Luca VD, Remington G, Graff-Guerrero A. SU118. Cognitive Impairment and Clozapine Response in Treatment-Resistant Schizophrenia—A Cross-Sectional Study Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx024.114  1
2017 Iwata Y, Nakajima S, Plitman E, Mihashi Y, Caravaggio F, Chung JK, Kim J, Gerretsen P, Mimura M, Remington G, Graff-Guerrero A. SU84. Neurometabolite Levels in Antipsychotic Naive/Free Patients With Schizophrenia: A Meta-Analysis of 1H-MRS Studies. Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx024.080  1
2017 Caravaggio F, Mar W, Remington G, Graff-Guerrero A, Menon M. SA118. Intranasal Oxytocin Does Not Modulate Jumping to Conclusion: S in Schizophrenia: Potential Interaction With Baseline Social Functioning. Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx023.114  1
2017 Silva SD, Saperia S, Apatsidou A, Siddiqui I, Fervaha G, Agid O, Daskalakis Z, Ravindran A, Voineskos A, Zakzanis K, Remington G, Foussias G. SA109. Examining Reward Responsiveness and Expectancy Across a Dimension of Motivation Deficits in Schizophrenia Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx023.107  1
2017 Remington G. 168. Neuroadaptations to Antipsychotic Drugs: Optimizing use of Current Medication Through a Deeper Understanding of Antipsychotic Drug Action in the Brain and Body Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx021.226  0.01
2016 Lee J, Takeuchi H, Fervaha G, Sin GL, Foussias G, Agid O, Farooq S, Remington G. Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. Focus (American Psychiatric Publishing). 14: 396-402. PMID 31997961 DOI: 10.1176/appi.focus.140306  1
2016 Korostil M, Remington G, McIntosh AR. Practice and Learning: Spatiotemporal Differences in Thalamo-Cortical-Cerebellar Networks Engagement across Learning Phases in Schizophrenia. Frontiers in Psychiatry. 7: 212. PMID 28167919 DOI: 10.3389/Fpsyt.2016.00212  1
2016 Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, ... ... Remington G, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. The American Journal of Psychiatry. appiajp201616050503. PMID 27919182 DOI: 10.1176/Appi.Ajp.2016.16050503  1
2016 Schulze L, Remington G, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J. Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression. Journal of Psychopharmacology (Oxford, England). PMID 27852961 DOI: 10.1177/0269881116675516  1
2016 Subramaniapillai M, Tremblay L, Grassmann V, Remington G, Faulkner G. The effect of an acute bout of exercise on executive function among individuals with schizophrenia. Psychiatry Research. PMID 27838019 DOI: 10.1016/J.Psychres.2016.10.075  1
2016 Takeuchi H, Fervaha G, Remington G. Incidence of Antipsychotic-Associated Side Effects: Impact of Clinician Versus Patient Ratings and Change Versus Absolute Scores. Journal of Clinical Psychopharmacology. PMID 27626285 DOI: 10.1097/Jcp.0000000000000569  1
2016 Duncan MJ, Arbour-Nicitopoulos K, Subramanieapillai M, Remington G, Faulkner G. Revisiting the International Physical Activity Questionnaire (IPAQ): Assessing physical activity among individuals with schizophrenia. Schizophrenia Research. PMID 27623360 DOI: 10.1016/J.Schres.2016.09.010  1
2016 Hafizi S, Tseng HH, Rao N, Selvanathan T, Kenk M, Bazinet RP, Suridjan I, Wilson AA, Meyer JH, Remington G, Houle S, Rusjan PM, Mizrahi R. Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [(18)F]FEPPA. The American Journal of Psychiatry. appiajp201616020171. PMID 27609240 DOI: 10.1176/Appi.Ajp.2016.16020171  1
2016 Lister J, Andreazza AC, Navaid B, Wilson VS, Teo C, Nesarajah Y, Wilson AA, Nobrega JN, Fletcher PJ, Remington G. Lipoic Acid and Haloperidol-Induced Vacuous Chewing Movements: Implications for Prophylactic Antioxidant Use in Tardive Dyskinesia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 27565433 DOI: 10.1016/J.Pnpbp.2016.08.010  1
2016 Fervaha G, Caravaggio F, Mamo DC, Mulsant BH, Pollock BG, Nakajima S, Gerretsen P, Rajji TK, Mar W, Iwata Y, Plitman E, Chung JK, Remington G, Graff-Guerrero A. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. Psychopharmacology. PMID 27557949 DOI: 10.1007/S00213-016-4415-6  1
2016 Takeuchi H, Fervaha G, Remington G. Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratings. Psychiatry Research. 244: 415-419. PMID 27543916 DOI: 10.1016/J.Psychres.2016.07.055  1
2016 Subramaniapillai M, Arbour-Nicitopoulos K, Duncan M, McIntyre RS, Mansur RB, Remington G, Faulkner G. Physical activity preferences of individuals diagnosed with schizophrenia or bipolar disorder. Bmc Research Notes. 9: 340. PMID 27405745 DOI: 10.1186/S13104-016-2151-Y  1
2016 Remington G, Foussias G, Fervaha G, Agid O, Takeuchi H, Lee J, Hahn M. Treating Negative Symptoms in Schizophrenia: an Update. Current Treatment Options in Psychiatry. 3: 133-150. PMID 27376016 DOI: 10.1007/S40501-016-0075-8  1
2016 Duncan MJ, Arbour-Nicitopoulos K, Subramanieapillai M, Remington G, Faulkner G. Comparative Validity of Physical Activity Assessment Methods for Individuals with Schizophrenia: 2695 Board #218 June 3, 11: 00 AM - 12: 30 PM. Medicine and Science in Sports and Exercise. 48: 754. PMID 27361331 DOI: 10.1249/01.Mss.0000487264.76746.F6  1
2016 Grassmann V, Subramaniapillai M, Duncan M, Fervaha G, Remington G, Arbour-Nicitopoulos K, Faulkner GE. The Relationship Between Moderate-to-Vigorous Physical Activity and Executive Function Among Individuals with Schizophrenia: 1156 June 1, 3: 45 PM - 4: 00 PM. Medicine and Science in Sports and Exercise. 48: 316. PMID 27360191 DOI: 10.1249/01.mss.0000485953.51908.63  1
2016 Caravaggio F, Kegeles LS, Wilson AA, Remington G, Borlido C, Mamo DC, Graff-Guerrero A. Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain. Synapse (New York, N.Y.). PMID 27341789 DOI: 10.1002/Syn.21920  1
2016 Takeuchi H, Fervaha G, Lee J, Agid O, Remington G. A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD). Journal of Psychiatric Research. 80: 87-92. PMID 27318892 DOI: 10.1016/J.Jpsychires.2016.06.005  1
2016 Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Life satisfaction and happiness among young adults with schizophrenia. Psychiatry Research. 242: 174-179. PMID 27288735 DOI: 10.1016/J.Psychres.2016.05.046  1
2016 Takeuchi H, Fervaha G, Lee J, Remington G. What symptom domains are associated with patient distress in schizophrenia? Schizophrenia Research. PMID 27261417 DOI: 10.1016/J.Schres.2016.05.020  1
2016 Benarroch L, Kowalchuk C, Wilson V, Teo C, Guenette M, Chintoh A, Nesarajah Y, Taylor V, Selby P, Fletcher P, Remington GJ, Hahn MK. Atypical antipsychotics and effects on feeding: from mice to men. Psychopharmacology. PMID 27251130 DOI: 10.1007/S00213-016-4324-8  1
2016 Fervaha G, Takeuchi H, Foussias G, Agid O, Remington G. Using poverty of speech as a case study to explore the overlap between negative symptoms and cognitive dysfunction. Schizophrenia Research. PMID 27242067 DOI: 10.1016/J.Schres.2016.05.019  1
2016 Remington G, Lee J, Agid O, Takeuchi H, Foussias G, Hahn M, Fervaha G, Burton L, Powell V. Clozapine's Critical Role in Treatment Resistant Schizophrenia: Ensuring Both Safety and Use. Expert Opinion On Drug Safety. PMID 27207070 DOI: 10.1080/14740338.2016.1191468  1
2016 Oh N, See YM, Remington G, Lee J. Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia. Journal of Clinical Psychopharmacology. PMID 27187561 DOI: 10.1097/Jcp.0000000000000513  1
2016 Lee J, Remington G. Drs Lee and Remington Reply. The Journal of Clinical Psychiatry. 77: e468. PMID 27137432 DOI: 10.4088/Jcp.15Lr10392A  1
2016 Lee J, Bies R, Takeuchi H, Fervaha G, Bhaloo A, Powell V, Remington G. Quantifying intraindividual variations in plasma clozapine levels: a population pharmacokinetic approach. The Journal of Clinical Psychiatry. PMID 27136679 DOI: 10.4088/Jcp.14M09714  1
2016 Takeuchi H, Fervaha G, Remington G. Consistency between clinician and patient ratings of clozapine-induced side effects. Schizophrenia Research. PMID 27091657 DOI: 10.1016/J.Schres.2016.04.005  1
2016 Fervaha G, Foussias G, Takeuchi H, Agid O, Remington G. Motivational deficits in major depressive disorder: Cross-sectional and longitudinal relationships with functional impairment and subjective well-being. Comprehensive Psychiatry. 66: 31-8. PMID 26995233 DOI: 10.1016/J.Comppsych.2015.12.004  1
2016 Taylor DL, Tiwari AK, Lieberman JA, Potkin SG, Meltzer HY, Knight J, Remington G, Müller DJ, Kennedy JL. Genetic association analysis of N-methyl-d-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. Human Psychopharmacology. PMID 26876050 DOI: 10.1002/Hup.2519  1
2016 Duncan MJ, Faulkner G, Remington G, Arbour-Nicitopoulos K. Characterizing the affective responses to an acute bout of moderate-intensity exercise among outpatients with schizophrenia. Psychiatry Research. PMID 26851964 DOI: 10.1016/J.Psychres.2016.01.030  1
2016 Borlido C, Remington G, Graff-Guerrero A, Arenovich T, Hazra M, Wong A, Daskalakis ZJ, Mamo DC. Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 77: e14-20. PMID 26845273 DOI: 10.4088/Jcp.14M09321  1
2016 Koga AT, Strauss J, Zai C, Remington G, De Luca V. Genome-wide association analysis to predict optimal antipsychotic dosage in schizophrenia: a pilot study. Journal of Neural Transmission (Vienna, Austria : 1996). 123: 329-38. PMID 26821981 DOI: 10.1007/S00702-015-1472-7  1
2016 Mccormick PN, Fletcher PJ, Wilson VS, Remington GJ. The adrenergic α2 antagonist atipamezole alters the behavioural effects of pramipexole and increases pramipexole concentration in blood plasma Life Sciences. 151: 300-304. DOI: 10.1016/j.lfs.2016.03.017  1
2015 Siu CO, Harvey PD, Agid O, Waye M, Brambilla C, Choi WK, Remington G. Insight and subjective measures of quality of life in chronic schizophrenia. Schizophrenia Research. Cognition. 2: 127-132. PMID 26973810 DOI: 10.1016/J.Scog.2015.05.002  1
2015 Lee J, Takeuchi H, Fervaha G, Sin GL, Foussias G, Agid O, Farooq S, Remington G. Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 60: 515-522. PMID 26720509 DOI: 10.1177/070674371506001107  1
2015 Agid O, Mcdonald K, Fervaha G, Littrell R, Thoma J, Zipursky RB, Foussias G, Remington G. Values in First-Episode Schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 60: 507-14. PMID 26720508  1
2015 Behdinan T, Foussias G, Wheeler AL, Stefanik L, Felsky D, Remington G, Rajji TK, Mallar Chakravarty M, Voineskos AN. Neuroimaging predictors of functional outcomes in schizophrenia at baseline and 6-month follow-up. Schizophrenia Research. PMID 26603060 DOI: 10.1016/J.Schres.2015.10.023  1
2015 Lam M, Abdul Rashid NA, Lee SA, Lim J, Foussias G, Fervaha G, Ruhrman S, Remington G, Lee J. Baseline social amotivation predicts 1-year functioning in UHR subjects: A validation and prospective investigation. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 26553972 DOI: 10.1016/J.Euroneuro.2015.10.007  1
2015 Takeuchi H, Fervaha G, Remington G. Effect of Antipsychotic Dosing Regimen on Neurocognition in Schizophrenia. Journal of Clinical Psychopharmacology. 35: 728-30. PMID 26479222 DOI: 10.1097/Jcp.0000000000000424  1
2015 Takeuchi H, Remington G. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction. Evidence-Based Mental Health. 18: 117. PMID 26459470 DOI: 10.1136/eb-2015-102209  1
2015 Fervaha G, Foussias G, Takeuchi H, Agid O, Remington G. Measuring motivation in people with schizophrenia. Schizophrenia Research. PMID 26391283 DOI: 10.1016/J.Schres.2015.09.012  1
2015 Fervaha G, Zakzanis KK, Foussias G, Agid O, Remington G. Distress related to subclinical negative symptoms in a non-clinical sample: Role of dysfunctional attitudes. Psychiatry Research. 230: 249-54. PMID 26365687 DOI: 10.1016/J.Psychres.2015.09.002  1
2015 Remington GJ, Teo C, Wilson V, Chintoh A, Guenette M, Ahsan Z, Giacca A, Hahn MK. Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. The Journal of Endocrinology. 227: 71-81. PMID 26330531 DOI: 10.1530/Joe-15-0074  1
2015 Lee J, Bies R, Bhaloo A, Powell V, Remington G. Clozapine and anemia: a 2-year follow-up study. The Journal of Clinical Psychiatry. PMID 26301364 DOI: 10.4088/Jcp.14M09143  1
2015 Lee J, Takeuchi H, Fervaha G, Powell V, Bhaloo A, Bies R, Remington G. The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study. Journal of Clinical Psychopharmacology. 35: 510-6. PMID 26267420 DOI: 10.1097/Jcp.0000000000000387  1
2015 Fervaha G, Agid O, Foussias G, Siddiqui I, Takeuchi H, Remington G. Neurocognitive impairment in the deficit subtype of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. PMID 26260899 DOI: 10.1007/S00406-015-0629-6  1
2015 Remington G, Seeman MV. Schizophrenia and the Influence of Male Gender Clinical Pharmacology and Therapeutics. 98: 578-581. PMID 26260896 DOI: 10.1002/Cpt.201  1
2015 Fervaha G, Duncan M, Foussias G, Agid O, Faulkner GE, Remington G. Effort-based decision making as an objective paradigm for the assessment of motivational deficits in schizophrenia. Schizophrenia Research. 168: 483-90. PMID 26215506 DOI: 10.1016/J.Schres.2015.07.023  1
2015 Takeuchi H, Suzuki T, Remington G, Uchida H. Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 60: 215-22. PMID 26174525  1
2015 Lockwood JT, Remington G. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. Expert Opinion On Emerging Drugs. 20: 407-21. PMID 26166007 DOI: 10.1517/14728214.2015.1050376  1
2015 Spadaro A, Kellar J, Remington G, Sproule B, Al-Sukhni M, Chaiet A. Evaluation of an Educational Program for Clinical Pharmacists to Conduct Standardized Assessments for Medication-Induced Movement-Related Disorders. The Canadian Journal of Hospital Pharmacy. 68: 258-64. PMID 26157190  1
2015 Fervaha G, Siddiqui I, Foussias G, Agid O, Remington G. Motivation and Social Cognition in Patients with Schizophrenia. Journal of the International Neuropsychological Society : Jins. 21: 436-43. PMID 26135736 DOI: 10.1017/S1355617715000375  1
2015 Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. Medical Hypotheses. PMID 26118462 DOI: 10.1016/J.Mehy.2015.06.011  1
2015 Foussias G, Siddiqui I, Fervaha G, Mann S, McDonald K, Agid O, Zakzanis KK, Remington G. Motivated to do well: an examination of the relationships between motivation, effort, and cognitive performance in schizophrenia. Schizophrenia Research. 166: 276-82. PMID 26008882 DOI: 10.1016/J.Schres.2015.05.019  1
2015 Fervaha G, Hill C, Agid O, Takeuchi H, Foussias G, Siddiqui I, Kern RS, Remington G. Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. Schizophrenia Research. 166: 304-9. PMID 26004693 DOI: 10.1016/J.Schres.2015.05.015  1
2015 Fervaha G, Foussias G, Agid O, Remington G. Motivational deficits in early schizophrenia: prevalent, persistent, and key determinants of functional outcome. Schizophrenia Research. 166: 9-16. PMID 25982811 DOI: 10.1016/J.Schres.2015.04.040  1
2015 Siu CO, Agid O, Remington G. Measuring the effects of treatment with antipsychotics. Jama Psychiatry. 72: 514-5. PMID 25945491 DOI: 10.1001/Jamapsychiatry.2014.3134  1
2015 Remington G, Agid O, Foussias G, Fervaha G, Takeuchi H, Lee J, Hahn M. What does schizophrenia teach us about antipsychotics? Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 60: S14-8. PMID 25886675  1
2015 Tsuboi T, Suzuki T, Bies RR, Remington G, Pollock BG, Mimura M, Uchida H. Challenging the need for sustained blockade of dopamine D₂ receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. Schizophrenia Research. 164: 149-54. PMID 25864950 DOI: 10.1016/J.Schres.2015.03.025  1
2015 Rajji TK, Mulsant BH, Davies S, Kalache SM, Tsoutsoulas C, Pollock BG, Remington G. Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. The American Journal of Psychiatry. 172: 579-85. PMID 25859763 DOI: 10.1176/Appi.Ajp.2015.14050673  1
2015 Lee J, Fervaha G, Takeuchi H, Powell V, Remington G. Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia. Journal of Clinical Psychopharmacology. 35: 237-41. PMID 25839337 DOI: 10.1097/Jcp.0000000000000310  1
2015 Wheeler AL, Wessa M, Szeszko PR, Foussias G, Chakravarty MM, Lerch JP, DeRosse P, Remington G, Mulsant BH, Linke J, Malhotra AK, Voineskos AN. Further neuroimaging evidence for the deficit subtype of schizophrenia: a cortical connectomics analysis. Jama Psychiatry. 72: 446-55. PMID 25786193 DOI: 10.1001/Jamapsychiatry.2014.3020  1
2015 Strassnig M, Clarke J, Mann S, Remington G, Ganguli R. Body composition, pre-diabetes and cardiovascular disease risk in early schizophrenia. Early Intervention in Psychiatry. PMID 25752319 DOI: 10.1111/eip.12225  1
2015 Moriguchi S, Bies RR, Remington G. Erratum: Estimated dopamine D2 Receptor Occupancy and Remission in Schizophrenia. Analysis of the CATIE Data (Journal of Clinical Psychopharmacology (2013) 33 (682-685)) Journal of Clinical Psychopharmacology. 35. PMID 25719960 DOI: 10.1097/01.Jcp.0000462421.30671.09  1
2015 Caravaggio F, Borlido C, Hahn M, Feng Z, Fervaha G, Gerretsen P, Nakajima S, Plitman E, Chung JK, Iwata Y, Wilson A, Remington G, Graff-Guerrero A. Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 18: pyv014. PMID 25716779 DOI: 10.1093/Ijnp/Pyv014  1
2015 Lee J, Remington G. Schizophrenia as a lifelong illness: implications for care. Annals of the Academy of Medicine, Singapore. 44: 26-8. PMID 25703494  1
2015 Nakajima S, Takeuchi H, Plitman E, Fervaha G, Gerretsen P, Caravaggio F, Chung JK, Iwata Y, Remington G, Graff-Guerrero A. Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophrenia Research. 164: 164-75. PMID 25684554 DOI: 10.1016/J.Schres.2015.01.043  1
2015 Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Remington G. Relationship between symptomatic improvement and overall illness severity in patients with schizophrenia. Journal of Clinical Psychopharmacology. 35: 128-33. PMID 25679125 DOI: 10.1097/Jcp.0000000000000286  1
2015 Fervaha G, Agid O, Takeuchi H, Foussias G, Lee J, Remington G. Clinical and functional outcomes in people with schizophrenia with a high sense of well-being. The Journal of Nervous and Mental Disease. 203: 187-93. PMID 25668654 DOI: 10.1097/Nmd.0000000000000266  1
2015 Lister J, Fletcher PJ, Nobrega JN, Remington G. Behavioral effects of food-derived opioid-like peptides in rodents: Implications for schizophrenia? Pharmacology, Biochemistry, and Behavior. 134: 70-78. PMID 25661529 DOI: 10.1016/J.Pbb.2015.01.020  1
2015 Sinyor M, Schaffer A, Remington G. Suicide in schizophrenia: an observational study of coroner records in Toronto. The Journal of Clinical Psychiatry. 76: e98-103. PMID 25650686 DOI: 10.4088/Jcp.14M09047  1
2015 Takeuchi H, Fervaha G, Lee J, Agid O, Remington G. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 295-302. PMID 25649680 DOI: 10.1016/J.Euroneuro.2014.12.008  1
2015 Fervaha G, Takeuchi H, Lee J, Foussias G, Fletcher PJ, Agid O, Remington G. Antipsychotics and amotivation. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1539-48. PMID 25567425 DOI: 10.1038/Npp.2015.3  1
2015 Nakajima S, Takeuchi H, Fervaha G, Plitman E, Chung JK, Caravaggio F, Iwata Y, Mihashi Y, Gerretsen P, Remington G, Mulsant B, Graff-Guerrero A. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. Schizophrenia Research. 161: 429-33. PMID 25556080 DOI: 10.1016/J.Schres.2014.12.024  1
2015 Foussias G, Siddiqui I, Fervaha G, Agid O, Remington G. Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments. Journal of Psychopharmacology (Oxford, England). 29: 116-26. PMID 25516370 DOI: 10.1177/0269881114562092  1
2015 Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Zakzanis KK, Graff-Guerrero A, Remington G. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. Schizophrenia Research. 161: 351-6. PMID 25471015 DOI: 10.1016/J.Schres.2014.11.018  1
2015 Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G, Meyer JH, Wilson AA, Houle S, Mizrahi R. Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. Schizophrenia Bulletin. 41: 85-93. PMID 25385788 DOI: 10.1093/schbul/sbu157  1
2015 McCormick PN, Fletcher PJ, Wilson VS, Browne JD, Nobrega JN, Remington GJ. Low dose pramipexole causes D3 receptor-independent reduction of locomotion and responding for a conditioned reinforcer. Neuropharmacology. 89: 225-31. PMID 25283483 DOI: 10.1016/J.Neuropharm.2014.09.026  1
2015 Gerretsen P, Menon M, Chakravarty MM, Lerch JP, Mamo DC, Remington G, Pollock BG, Graff-Guerrero A. Illness denial in schizophrenia spectrum disorders: a function of left hemisphere dominance. Human Brain Mapping. 36: 213-25. PMID 25209949 DOI: 10.1002/Hbm.22624  1
2015 Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, MasaruMimura, Uchida H. Corrigendum to Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: An analysis of the CATIE data [Schizophr. Res. 150 (2-3), November 2013, Pages 373-379], DOI: 10.1016/j.schres.2013.08.033 Schizophrenia Research. 162: 296. DOI: 10.1016/J.Schres.2015.01.011  1
2015 Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia Medical Hypotheses. DOI: 10.1016/j.mehy.2015.06.011  1
2014 Fervaha G, Takeuchi H, Agid O, Lee J, Foussias G, Remington G. Determinants of patient-rated and clinician-rated illness severity in schizophrenia. The Journal of Clinical Psychiatry. PMID 25562591 DOI: 10.4088/Jcp.14M09128  1
2014 Gerretsen P, Menon M, Mamo DC, Fervaha G, Remington G, Pollock BG, Graff-Guerrero A. Impaired insight into illness and cognitive insight in schizophrenia spectrum disorders: resting state functional connectivity. Schizophrenia Research. 160: 43-50. PMID 25458571 DOI: 10.1016/J.Schres.2014.10.015  1
2014 Gerretsen P, Remington G, Borlido C, Quilty L, Hassan S, Polsinelli G, Teo C, Mar W, Simon R, Menon M, Pothier DD, Nakajima S, Caravaggio F, Mamo DC, Rajji TK, et al. The VAGUS insight into psychosis scale--self-report and clinician-rated versions. Psychiatry Research. 220: 1084-9. PMID 25246410 DOI: 10.1016/J.Psychres.2014.08.005  1
2014 Gorczynski P, Faulkner G, Cohn T, Remington G. Examining strategies to improve accelerometer compliance for individuals living with schizophrenia. Psychiatric Rehabilitation Journal. 37: 333-5. PMID 25243343 DOI: 10.1037/Prj0000093  1
2014 Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J, Chung JK, Caravaggio F, Iwata Y, Remington G, Graff-Guerrero A. Glutamate-mediated excitotoxicity in schizophrenia: a review. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1591-605. PMID 25159198 DOI: 10.1016/J.Euroneuro.2014.07.015  1
2014 Lee J, Takeuchi H, Fervaha G, Bhaloo A, Powell V, Remington G. Relationship between clinical improvement and functional gains with clozapine in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1622-9. PMID 25156578 DOI: 10.1016/J.Euroneuro.2014.08.003  1
2014 Li CH, Stratford RE, Velez de Mendizabal N, Cremers TI, Pollock BG, Mulsant BH, Remington G, Bies RR. Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics. Journal of Translational Medicine. 12: 203. PMID 25142323 DOI: 10.1186/1479-5876-12-203  1
2014 Takeuchi H, Suzuki T, Bies RR, Remington G, Watanabe K, Mimura M, Uchida H. Dose reduction of risperidone and olanzapine and estimated dopamine Dâ‚‚ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. The Journal of Clinical Psychiatry. 75: 1209-14. PMID 25099201 DOI: 10.4088/Jcp.13M08841  1
2014 Fervaha G, Zakzanis KK, Foussias G, Graff-Guerrero A, Agid O, Remington G. Motivational deficits and cognitive test performance in schizophrenia. Jama Psychiatry. 71: 1058-65. PMID 25075930 DOI: 10.1001/Jamapsychiatry.2014.1105  1
2014 Hettige NC, Zai C, Hazra M, Borlido C, Kennedy JL, Strauss J, Le Foll B, Wong A, Remington G, De Luca V. Use of candidate gene markers to guide antipsychotic dosage adjustment. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 54: 315-20. PMID 25016278 DOI: 10.1016/j.pnpbp.2014.07.001  1
2014 Lee J, Bhaloo A, Powell V, Remington G. Therapeutic drug monitoring of clozapine: sampling error as a source of variance. Therapeutic Drug Monitoring. 36: 829-31. PMID 24977382 DOI: 10.1097/Ftd.0000000000000111  1
2014 Arbour-Nicitopoulos KP, Duncan M, Remington G, Cairney J, Faulkner GE. Development and Reliability Testing of a Health Action Process Approach Inventory for Physical Activity Participation among Individuals with Schizophrenia. Frontiers in Psychiatry. 5: 68. PMID 24959152 DOI: 10.3389/Fpsyt.2014.00068  1
2014 Lee J, Lee TS, Remington G. Schizophrenia: no health without physical health. Annals of the Academy of Medicine, Singapore. 43: 248-9. PMID 24919488  1
2014 Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H. Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia. Journal of Clinical Psychopharmacology. 34: 517-20. PMID 24911439 DOI: 10.1097/Jcp.0000000000000142  1
2014 Lee J, Powell V, Remington G. Mean platelet volume in schizophrenia unaltered after 1year of clozapine exposure. Schizophrenia Research. 157: 134-6. PMID 24906221 DOI: 10.1016/J.Schres.2014.04.038  1
2014 Lee J, Takeuchi H, Remington G. Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls. Journal of Clinical Psychopharmacology. 34: 530-2. PMID 24875070 DOI: 10.1097/Jcp.0000000000000149  1
2014 Caravaggio F, Nakajima S, Borlido C, Remington G, Gerretsen P, Wilson A, Houle S, Menon M, Mamo D, Graff-Guerrero A. Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 2769-76. PMID 24874713 DOI: 10.1038/Npp.2014.125  1
2014 Fervaha G, Foussias G, Agid O, Remington G. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia Acta Psychiatrica Scandinavica. 130: 290-299. PMID 24850369 DOI: 10.1111/Acps.12289  1
2014 Fervaha G, Agid O, McDonald K, Foussias G, Remington G. Daily activity patterns in remitted first-episode schizophrenia. Comprehensive Psychiatry. 55: 1182-7. PMID 24813789 DOI: 10.1016/J.Comppsych.2014.04.001  1
2014 Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H. Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. Psychiatry Research. 218: 244-6. PMID 24768247 DOI: 10.1016/j.psychres.2014.04.019  1
2014 Lister J, Nobrega JN, Fletcher PJ, Remington G. Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. Psychopharmacology. 231: 2237-49. PMID 24752659 DOI: 10.1007/S00213-014-3582-6  1
2014 Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1078-85. PMID 24726579 DOI: 10.1016/J.Euroneuro.2014.03.001  1
2014 Fervaha G, Foussias G, Siddiqui I, Agid O, Remington G. Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures. Schizophrenia Research. 154: 89-92. PMID 24630140 DOI: 10.1016/J.Schres.2014.02.013  1
2014 Remington G, Foussias G, Fervaha G, Agid O. Schizophrenia, cognition, and psychosis. Jama Psychiatry. 71: 336-7. PMID 24599240 DOI: 10.1001/jamapsychiatry.2013.3532  1
2014 Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies RR, Grönte D, Remington G. Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. The Journal of Clinical Psychiatry. 75: 506-11. PMID 24569099 DOI: 10.4088/Jcp.13M08695  1
2014 Fervaha G, Agid O, Foussias G, Remington G. Toward a more parsimonious assessment of neurocognition in schizophrenia: a 10-minute assessment tool. Journal of Psychiatric Research. 52: 50-6. PMID 24507885 DOI: 10.1016/J.Jpsychires.2014.01.009  1
2014 Yoshida K, Bies RR, Suzuki T, Remington G, Pollock BG, Mizuno Y, Mimura M, Uchida H. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Schizophrenia Research. 153: 184-8. PMID 24491908 DOI: 10.1016/J.Schres.2014.01.017  1
2014 Guenette MD, Chintoh A, Remington G, Hahn M. Atypical antipsychotic-induced metabolic disturbances in the elderly. Drugs & Aging. 31: 159-84. PMID 24477569 DOI: 10.1007/S40266-014-0152-X  1
2014 Remington G, Fervaha G, Foussias G, Agid O, Turrone P. Antipsychotic dosing: found in translation. Journal of Psychiatry & Neuroscience : Jpn. 39: 223-31. PMID 24467943 DOI: 10.1503/Jpn.130191  1
2014 Lee J, Nurjono M, Tay YH, Lee TS, Remington G. A comparison of cardio-metabolic risk between the deficit and non-deficit subtypes of schizophrenia. Schizophrenia Research. 153: 246-7. PMID 24451398 DOI: 10.1016/J.Schres.2014.01.007  1
2014 Lee J, Remington G. Adequate dosing for second-generation antipsychotics in establishing treatment resistance in schizophrenia. The American Journal of Psychiatry. 171: 118-9. PMID 24399431 DOI: 10.1176/Appi.Ajp.2013.13070965  1
2014 Remington G, Hahn M. Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects. Journal of Psychiatry & Neuroscience : Jpn. 39: E1-2. PMID 24359929 DOI: 10.1503/Jpn.130222  1
2014 Rao NP, Remington G. Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials. Expert Opinion On Pharmacotherapy. 15: 373-83. PMID 24354659 DOI: 10.1517/14656566.2014.873790  1
2014 Fervaha G, Agid O, Foussias G, Remington G. Effect of intrinsic motivation on cognitive performance in schizophrenia: a pilot study. Schizophrenia Research. 152: 317-8. PMID 24333003 DOI: 10.1016/J.Schres.2013.11.037  1
2014 Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 693-709. PMID 24275699 DOI: 10.1016/J.Euroneuro.2013.10.017  1
2014 Remington G, Foussias G, Agid O, Fervaha G, Takeuchi H, Hahn M. The neurobiology of relapse in schizophrenia. Schizophrenia Research. 152: 381-90. PMID 24206930 DOI: 10.1016/J.Schres.2013.10.009  1
2014 Callaghan RC, Veldhuizen S, Jeysingh T, Orlan C, Graham C, Kakouris G, Remington G, Gatley J. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. Journal of Psychiatric Research. 48: 102-10. PMID 24139811 DOI: 10.1016/j.jpsychires.2013.09.014  1
2014 Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, Fletcher P, Lam L, Nobrega J, Guenette M, Cohn T, Giacca A. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 448-58. PMID 24001874 DOI: 10.1016/J.Euroneuro.2013.07.011  1
2014 Fervaha G, Agid O, Foussias G, Graff-Guerrero A, Zakzanis K, Remington G. Poster #T76 BEHAVIOURAL ECONOMICS OF EFFORT-BASED REWARD-DRIVEN CHOICE IN SCHIZOPHRENIA Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70893-X  1
2014 Siu CO, Harvey PD, Agid O, Waye M, Brambilla C, Choi WK, Remington G. Insight and subjective measures of quality of life in chronic schizophrenia Schizophrenia Research: Cognition. DOI: 10.1016/j.scog.2015.05.002  1
2014 Gorczynski P, Faulkner G, Cohn T, Remington G. Examining the efficacy and feasibility of exercise counseling in individuals with schizophrenia: A single-case experimental study Mental Health and Physical Activity. 7: 191-197. DOI: 10.1016/J.Mhpa.2014.04.002  1
2014 Gerretsen P, Remington G, Borlido C, Quilty LC, Hassan S, Polsinelli G, Mar W, Teo C, Simon R, Pothier D, Menon M, Nakajima S, Caravaggio F, Mamo D, Rajji TK, et al. The VAGUS- Self-Report & Clinician-Rated Versions: A Novel Insight into Psychosis Scale for Use Across the Adult Late-Life Span American Journal of Geriatric Psychiatry. 22. DOI: 10.1016/J.Jagp.2013.12.107  1
2014 Fervaha G, Foussias G, Agid O, Remington G. Impact of primary negative symptoms on functional outcomes in schizophrenia European Psychiatry. DOI: 10.1016/J.Eurpsy.2014.01.007  1
2013 Zawadzki JA, Girard TA, Foussias G, Rodrigues A, Siddiqui I, Lerch JP, Grady C, Remington G, Wong AH. Simulating real world functioning in schizophrenia using a naturalistic city environment and single-trial, goal-directed navigation. Frontiers in Behavioral Neuroscience. 7: 180. PMID 24324418 DOI: 10.3389/Fnbeh.2013.00180  1
2013 Siu CO, Agid O, Remington G. Efficacy of antipsychotic drugs for schizophrenia. Lancet (London, England). 382: 1874. PMID 24315169 DOI: 10.1016/S0140-6736(13)62616-1  1
2013 Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study. Schizophrenia Research. 151: 203-8. PMID 24183751 DOI: 10.1016/J.Schres.2013.10.021  1
2013 Hahn MK, Wolever TM, Arenovich T, Teo C, Giacca A, Powell V, Clarke L, Fletcher P, Cohn T, McIntyre RS, Gomes S, Chintoh A, Remington GJ. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. Journal of Clinical Psychopharmacology. 33: 740-6. PMID 24100786 DOI: 10.1097/Jcp.0B013E31829E8333  1
2013 Farooq S, Agid O, Foussias G, Remington G. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophrenia Bulletin. 39: 1169-72. PMID 24045038 DOI: 10.1093/Schbul/Sbt137  1
2013 Fervaha G, Foussias G, Agid O, Remington G. Neural substrates underlying effort computation in schizophrenia. Neuroscience and Biobehavioral Reviews. 37: 2649-65. PMID 24035741 DOI: 10.1016/J.Neubiorev.2013.09.001  1
2013 Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Life satisfaction among individuals with schizophrenia in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study. The American Journal of Psychiatry. 170: 1061-2. PMID 24030617 DOI: 10.1176/Appi.Ajp.2013.13010060  1
2013 Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, Mimura M, Uchida H. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data. Schizophrenia Research. 150: 373-9. PMID 24028745 DOI: 10.1016/J.Schres.2013.08.033  1
2013 Zai CC, Tiwari AK, Mazzoco M, de Luca V, Müller DJ, Shaikh SA, Lohoff FW, Freeman N, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. Journal of Psychiatric Research. 47: 1760-5. PMID 24018103 DOI: 10.1016/J.Jpsychires.2013.07.025  1
2013 Fervaha G, Agid O, Foussias G, Remington G. Impairments in both reward and punishment guided reinforcement learning in schizophrenia. Schizophrenia Research. 150: 592-3. PMID 24016724 DOI: 10.1016/j.schres.2013.08.012  1
2013 Fervaha G, Graff-Guerrero A, Zakzanis KK, Foussias G, Agid O, Remington G. Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making. Journal of Psychiatric Research. 47: 1590-6. PMID 23992770 DOI: 10.1016/J.Jpsychires.2013.08.003  1
2013 Chan LF, Zai C, Monda M, Potkin S, Kennedy JL, Remington G, Lieberman J, Meltzer HY, De Luca V. Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics. 14: 1273-81. PMID 23930674 DOI: 10.2217/Pgs.13.127  1
2013 Fervaha G, Foussias G, Agid O, Remington G. Amotivation and functional outcomes in early schizophrenia. Psychiatry Research. 210: 665-8. PMID 23911005 DOI: 10.1016/J.Psychres.2013.07.024  1
2013 Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, Mimura M, Pollock BG, Uchida H. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data. Journal of Clinical Psychopharmacology. 33: 682-5. PMID 23899638 DOI: 10.1097/Jcp.0B013E3182979A0A  1
2013 Agid O, Siu CO, Potkin SG, Kapur S, Watsky E, Vanderburg D, Zipursky RB, Remington G. Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. The American Journal of Psychiatry. 170: 1335-44. PMID 23896810 DOI: 10.1176/Appi.Ajp.2013.12030315  1
2013 Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, Watanabe K, Mimura M, Uchida H. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia Bulletin. 39: 993-8. PMID 23821768 DOI: 10.1093/Schbul/Sbt090  1
2013 Fervaha G, Remington G. Invalid responding in questionnaire-based research: implications for the study of schizotypy. Psychological Assessment. 25: 1355-60. PMID 23815113 DOI: 10.1037/a0033520  1
2013 Takeuchi H, Remington G. A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology. 228: 175-85. PMID 23736279 DOI: 10.1007/s00213-013-3154-1  1
2013 Guenette MD, Powell V, Johnston K, Foussias G, Agid O, Hahn M, Takeuchi H, Remington G. Risk of neutropenia in a clozapine-treated elderly population. Schizophrenia Research. 148: 183-5. PMID 23727216 DOI: 10.1016/J.Schres.2013.05.001  1
2013 Agid O, Schulze L, Arenovich T, Sajeev G, McDonald K, Foussias G, Fervaha G, Remington G. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 1017-22. PMID 23706529 DOI: 10.1016/J.Euroneuro.2013.04.010  1
2013 Rao NP, Remington G. Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials Expert Opinion On Investigational Drugs. 22: 881-894. PMID 23639138 DOI: 10.1517/13543784.2013.795945  1
2013 Gorczynski PF, Faulkner GE, Cohn TA, Remington GJ. Effects of point-of-choice prompts on stair usage in a psychiatric setting. Psychiatric Services (Washington, D.C.). 64: 498. PMID 23632584 DOI: 10.1176/appi.ps.004582012  1
2013 Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh A, Arenovich T, Remington G. Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model. Schizophrenia Research. 146: 162-9. PMID 23499243 DOI: 10.1016/J.Schres.2013.02.023  1
2013 Voineskos AN, Foussias G, Lerch J, Felsky D, Remington G, Rajji TK, Lobaugh N, Pollock BG, Mulsant BH. Neuroimaging evidence for the deficit subtype of schizophrenia. Jama Psychiatry. 70: 472-80. PMID 23467781 DOI: 10.1001/Jamapsychiatry.2013.786  1
2013 Remington G, Teo C, Mann S, Hahn M, Foussias G, Agid O. Examining levels of antipsychotic adherence to better understand nonadherence. Journal of Clinical Psychopharmacology. 33: 261-3. PMID 23422390 DOI: 10.1097/Jcp.0B013E31828568Bc  1
2013 Suzuki T, Graff-Guerrero A, Uchida H, Remington G, Caravaggio F, Borlido C, Pollock B, Mulsant B, Deluca V, Ismail Z, Mamo D. Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. Psychopharmacology. 228: 43-51. PMID 23417515 DOI: 10.1007/S00213-013-3012-1  1
2013 Remington G, Agid O, Foussias G, Hahn M, Rao N, Sinyor M. Clozapine's role in the treatment of first-episode schizophrenia. The American Journal of Psychiatry. 170: 146-51. PMID 23377634 DOI: 10.1176/Appi.Ajp.2012.12060778  1
2013 Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology. 226: 1-12. PMID 23344556 DOI: 10.1007/S00213-013-2982-3  1
2013 Hahn MK, Cohn T, Teo C, Remington G. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. Clinical Schizophrenia & Related Psychoses. 6: 186-96. PMID 23302448 DOI: 10.3371/Csrp.Haco.01062013  1
2013 Fervaha G, Remington G. Validation of an abbreviated quality of life scale for schizophrenia European Neuropsychopharmacology. 23: 1072-1077. PMID 23235268 DOI: 10.1016/J.Euroneuro.2012.11.009  1
2013 Mann S, Chintoh A, Giacca A, Fletcher P, Nobrega J, Hahn M, Remington G. Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition. Pharmacology, Biochemistry, and Behavior. 103: 717-22. PMID 23234835 DOI: 10.1016/J.Pbb.2012.12.002  1
2013 Fervaha G, Remington G. Neuroimaging findings in schizotypal personality disorder: A systematic review Progress in Neuro-Psychopharmacology and Biological Psychiatry. 43: 96-107. PMID 23220094 DOI: 10.1016/J.Pnpbp.2012.11.014  1
2013 Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology. 225: 505-18. PMID 23179967 DOI: 10.1007/S00213-012-2922-7  1
2013 Menon M, Addington J, Remington G. Examining cognitive biases in patients with delusions of reference. European Psychiatry : the Journal of the Association of European Psychiatrists. 28: 71-3. PMID 21658918 DOI: 10.1016/J.Eurpsy.2011.03.005  1
2013 Siu CO, Agid O, Remington G. Authors' reply The Lancet. 382: 1874.  1
2012 Ikai S, Remington G, Suzuki T, Takeuchi H, Tsuboi T, Den R, Hirano J, Tsunoda K, Nishimoto M, Watanabe K, Mimura M, Mamo D, Uchida H. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: Implications for dopamine D 2 receptor occupancy during maintenance treatment in schizophrenia Journal of Clinical Psychiatry. 73: 1147-1152. PMID 22967779 DOI: 10.4088/Jcp.12M07638  1
2012 Yilmaz Z, Zai CC, Hwang R, Mann S, Arenovich T, Remington G, Daskalakis ZJ. Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis. Schizophrenia Research. 140: 214-20. PMID 22795368 DOI: 10.1016/J.Schres.2012.06.027  1
2012 Seeman P, Remington G. Antipsychotic dosing: Extended, and transient Clinical Schizophrenia and Related Psychoses. 6: 86-87. PMID 22776635 DOI: 10.3371/Csrp.6.2.6  1
2012 Gohlke JM, Dhurandhar EJ, Correll CU, Morrato EH, Newcomer JW, Remington G, Nasrallah HA, Crystal S, Nicol G, Allison DB. Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Frontiers in Psychiatry. 3: 62. PMID 22754543 DOI: 10.3389/Fpsyt.2012.00062  0.01
2012 Sinyor M, Remington G. Is psychiatry ignoring suicide?: The case for clozapine Journal of Clinical Psychopharmacology. 32: 307-308. PMID 22544020 DOI: 10.1097/Jcp.0B013E31825501Fb  1
2012 Taylor VH, McIntyre RS, Remington G, Levitan RD, Stonehocker B, Sharma AM. Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 57: 5-12. PMID 22296962 DOI: 10.1177/070674371205700103  1
2012 Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 37: 182-7. PMID 22230651 DOI: 10.1016/J.Pnpbp.2011.12.013  1
2012 Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, Boileau I, Kish SJ. Methamphetamine use and schizophrenia: a population-based cohort study in California. The American Journal of Psychiatry. 169: 389-96. PMID 22193527 DOI: 10.1176/Appi.Ajp.2011.10070937  1
2012 Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I, Pruessner JC, Remington G, Houle S, Wilson AA. Increased stress-induced dopamine release in psychosis. Biological Psychiatry. 71: 561-7. PMID 22133268 DOI: 10.1016/J.Biopsych.2011.10.009  1
2012 Tiwari AK, Zai CC, Likhodi O, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Müller DJ, Kennedy JL. Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. The Pharmacogenomics Journal. 12: 260-6. PMID 21266946 DOI: 10.1038/Tpj.2010.93  1
2012 Fervaha G, Remington G. Interpreting a multivariate analysis of functional neuroimaging data Frontiers in Psychiatry. 3. DOI: 10.3389/Fpsyt.2012.00052  1
2012 Agid O, Remington G. Commentry Evidence-Based Mental Health. 15: 92. DOI: 10.1136/Ebmental-2012-100906  1
2011 Suzuki T, Remington G, Uchida H, Rajji TK, Graff-Guerrero A, Mamo DC. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs & Aging. 28: 961-980. PMID 22117095 DOI: 10.2165/11595830-000000000-00000  1
2011 Remington G, Mann S, McCormick P, Nobrega JN, Hahn M, Natesan S. Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations. Pharmacology, Biochemistry, and Behavior. 100: 86-9. PMID 21839766 DOI: 10.1016/J.Pbb.2011.07.019  1
2011 Menon M, Schmitz TW, Anderson AK, Graff A, Korostil M, Mamo D, Gerretsen P, Addington J, Remington G, Kapur S. Exploring the neural correlates of delusions of reference. Biological Psychiatry. 70: 1127-33. PMID 21831358 DOI: 10.1016/J.Biopsych.2011.05.037  1
2011 Foussias G, Mann S, Zakzanis KK, Reekum Rv, Agid O, Remington G. Prediction of longitudinal functional outcomes in schizophrenia: The impact of baseline motivational deficits Schizophrenia Research. 132: 24-27. PMID 21771567 DOI: 10.1016/J.Schres.2011.06.026  1
2011 Hahn M, Chintoh A, Giacca A, Xu L, Lam L, Mann S, Fletcher P, Guenette M, Cohn T, Wolever T, Arenovich T, Remington G. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophrenia Research. 131: 90-5. PMID 21696923 DOI: 10.1097/01.Yic.0000405882.94837.86  1
2011 Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Houle S, Remington G, Wilson AA, Kapur S. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophrenia Research. 131: 63-68. PMID 21684721 DOI: 10.1016/J.Schres.2011.05.005  1
2011 Remington G, Agid O, Foussias G. Schizophrenia as a disorder of too little dopamine: Implications for symptoms and treatment Expert Review of Neurotherapeutics. 11: 589-607. PMID 21469931 DOI: 10.1586/ern.10.191  1
2011 Chowdhury NI, Remington G, Kennedy JL. Genetics of antipsychotic-induced side effects and agranulocytosis Current Psychiatry Reports. 13: 156-165. PMID 21336863 DOI: 10.1007/s11920-011-0185-3  1
2011 Souza RP, Meltzer HY, Lieberman JA, Voineskos AN, Remington G, Kennedy JL. Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective. Human Psychopharmacology. 26: 21-7. PMID 21305610 DOI: 10.1002/Hup.1161  1
2011 Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: A double-blind, placebo-controlled trial Journal of Clinical Psychiatry. 72: 1042-1048. PMID 20868639 DOI: 10.4088/JCP.09m05866yel  1
2011 Souza RP, Rosa DV, Romano-Silva MA, Zhen M, Meltzer HY, Lieberman JA, Remington G, Kennedy JL, Wong AH. Lack of association of NALCN genetic variants with schizophrenia. Psychiatry Research. 185: 450-2. PMID 20674038 DOI: 10.1016/J.Psychres.2010.07.009  1
2010 Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems Cochrane Database of Systematic Reviews (Online). 12. PMID 21154372 DOI: 10.1002/14651858.Cd006629.Pub2  1
2010 Hahn MK, Remington G, Bois D, Cohn T. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. Journal of Clinical Psychopharmacology. 30: 706-10. PMID 21105286 DOI: 10.1097/Jcp.0B013E3181Fab67D  1
2010 Agid O, Foussias G, Singh S, Remington G. Where to position clozapine: Re-examining the evidence Canadian Journal of Psychiatry. 55: 677-684. PMID 20964947 DOI: 10.1177/070674371005501007  1
2010 Remington G, Kapur S. Antipsychotic dosing: How much but also how often? Schizophrenia Bulletin. 36: 900-903. PMID 20650931 DOI: 10.1093/Schbul/Sbq083  1
2010 Sockalingam S, Shammi C, Powell V, Barker L, Remington G. Determining rates of hepatitis C in a clozapine treated cohort. Schizophrenia Research. 124: 86-90. PMID 20605572 DOI: 10.1016/J.Schres.2010.06.005  1
2010 Souza RP, Remington G, Chowdhury NI, Lau MK, Voineskos AN, Lieberman JA, Meltzer HY, Kennedy JL. Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20: 688-94. PMID 20605420 DOI: 10.1016/J.Euroneuro.2010.05.002  1
2010 Hahn MK, Cohn T, Remington G. Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. The Annals of Pharmacotherapy. 44: 1349-50; author repl. PMID 20587740 DOI: 10.1345/aph.1M550a  1
2010 Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: Their role in relapse prevention Expert Opinion On Pharmacotherapy. 11: 2301-2317. PMID 20586707 DOI: 10.1517/14656566.2010.499125  1
2010 Zai CC, Tiwari AK, Müller DJ, De Luca V, Shinkai T, Shaikh S, Ni X, Sibony D, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. The catechol-O-methyl-transferase gene in tardive dyskinesia. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 11: 803-12. PMID 20586531 DOI: 10.3109/15622975.2010.486043  1
2010 Remington G. Antipsychotic dosing: Still a work in progress American Journal of Psychiatry. 167: 623-625. PMID 20516160 DOI: 10.1176/Appi.Ajp.2010.10030302  1
2010 Souza RP, Remington G, Meltzer HY, Lieberman JA, Kennedy JL, Wong AH. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia. International Clinical Psychopharmacology. 25: 264-9. PMID 20436352 DOI: 10.1016/J.Schres.2010.02.586  1
2010 Foussias G, Remington G. Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making Canadian Journal of Psychiatry. 55: 117-125. PMID 20370961  1
2010 Souza RP, de Luca V, Remington G, Lieberman JA, Meltzer HY, Kennedy JL, Wong AH. Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. Psychopharmacology. 210: 347-54. PMID 20369355 DOI: 10.1007/S00213-010-1829-4  1
2010 Novak G, Gallo A, Zai CC, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, Remington G, Kennedy JL, Levesque D, Le Foll B. Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatric Genetics. 20: 39-43. PMID 20010315 DOI: 10.1097/Ypg.0B013E3283351221  1
2010 Foussias G, Remington G. Negative symptoms in schizophrenia: Avolition and occam's razor Schizophrenia Bulletin. 36: 359-369. PMID 18644851 DOI: 10.1093/Schbul/Sbn094  1
2010 Remington G, Foussias G, Agid O. Progress in defining optimal treatment outcome in schizophrenia Cns Drugs. 24: 9-20. DOI: 10.2165/11530250-000000000-00000  1
2010 Remington G. Augmenting clozapine response in treatment-resistant schizophrenia Therapy-Resistant Schizophrenia. 26: 129-151. DOI: 10.1159/000319813  1
2010 Agid O, Potkin S, Remington G, Kapur S, Vanderburg D, Watsky E, Siu C. Placebo Response In Antipsychotic Trials: A Systematic Review And Meta-Analysis Schizophrenia Research. 117: 492-492. DOI: 10.1016/J.Schres.2010.02.934  1
2009 Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G, Sproule B, Pollock BG, Mulsant BH, Bies RR. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Therapeutic Drug Monitoring. 31: 360-6. PMID 19349931 DOI: 10.1097/Ftd.0B013E31819C7037  1
2009 Courtney AM, Treadaway K, Remington G, Frohman E. Multiple Sclerosis Medical Clinics of North America. 93: 451-476. PMID 19272518 DOI: 10.1016/j.mcna.2008.09.014  1
2009 Zai CC, Tiwari AK, Basile V, De Luca V, Müller DJ, King N, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. The Pharmacogenomics Journal. 9: 168-74. PMID 19238168 DOI: 10.1038/Tpj.2009.2  1
2009 Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, Nobrega J, Remington G. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophrenia Research. 108: 127-33. PMID 19157785 DOI: 10.1016/J.Schres.2008.12.012  1
2009 Sockalingam S, Shammi C, Remington G. Treatment of clozapine-induced hypersalivation with ipratropium bromide: A randomized, double-blind, placebo-controlled crossover study Journal of Clinical Psychiatry. 70: 1114-1119. DOI: 10.4088/Jcp.08M04495  1
2009 Remington G. Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall ryRemington Evidence-Based Mental Health. 12: 51. DOI: 10.1136/ebmh.12.2.51  1
2009 Sockalingam S, Remington G. Review: Insufficient evidence to guide use of drugs for clozapine induced hypersalivation Evidence-Based Mental Health. 12: 12. DOI: 10.1136/Ebmh.12.1.12  1
2009 Remington G. From mice to men: What can animal models tell us about the relationship between mental health and physical activity? Mental Health and Physical Activity. 2: 10-15. DOI: 10.1016/J.Mhpa.2009.01.003  1
2008 Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, Nobrega JN, Giacca A, Remington G. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. Journal of Clinical Psychopharmacology. 28: 494-9. PMID 18794643 DOI: 10.1097/Jcp.0B013E318184B4C5  1
2008 Remington G. Alterations of dopamine and serotonin transmission in schizophrenia Progress in Brain Research. 172: 117-140. PMID 18772030 DOI: 10.1016/S0079-6123(08)00906-0  1
2008 Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia Expert Opinion On Emerging Drugs. 13: 479-495. PMID 18764724 DOI: 10.1517/14728214.13.3.479  1
2008 Seeman MV, Clodman D, Remington G. Transient tardive dystonia: overview and case presentation. Journal of Psychiatric Practice. 14: 251-7. PMID 18664896 DOI: 10.1097/01.Pra.0000327317.34647.28  1
2008 Mizrahi R, Addington J, Remington G, Kapur S. Attribution style as a factor in psychosis and symptom resolution Schizophrenia Research. 104: 220-227. PMID 18632256 DOI: 10.1016/J.Schres.2008.05.003  1
2008 Hazra M, Mamo DC, Remington G. Adjunctive versus monotherapeutic treatment for schizophrenia: Addressing antipsychotic side effects American Journal of Psychiatry. 165: 396-397. PMID 18316434 DOI: 10.1176/Appi.Ajp.2007.07111738  1
2008 Remington G, Kapur S. The Pharmacology of Typical and Atypical Antipsychotics Drug Induced Movement Disorders: Second Edition. 55-71. DOI: 10.1002/9780470753217.ch4  1
2007 Renou J, De Luca V, Zai CC, Bulgin N, Remington G, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. Molecular Psychiatry. 12: 1058-60. PMID 18043709 DOI: 10.1038/Sj.Mp.4002092  1
2007 Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: A review of treatment strategies Canadian Journal of Psychiatry. 52: 377-384. PMID 17696024 DOI: 10.1177/070674370705200607  1
2007 Remington G. Tardive dyskinesia: Eliminated, forgotten, or overshadowed? Current Opinion in Psychiatry. 20: 131-137. PMID 17278910 DOI: 10.1097/Yco.0B013E328017F6B1  1
2007 Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia Cochrane Database of Systematic Reviews (Online). PMID 17253540 DOI: 10.1002/14651858.Cd005148.Pub2  1
2007 Faulkner G, Cohn T, Remington G, Irving H. Body mass index, waist circumference and quality of life in individuals with schizophrenia Schizophrenia Research. 90: 174-178. PMID 17140768 DOI: 10.1016/J.Schres.2006.10.009  1
2007 Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 10: 639-51. PMID 16959057 DOI: 10.1017/S1461145706007152  1
2007 Remington G. Screening for a healthy future Menopause International. 13: 198. DOI: 10.1258/175404507783004050  1
2006 Remington G. Schizophrenia, antipsychotics, and the metabolic syndrome: Is there a silver lining? American Journal of Psychiatry. 163: 1132-1134. PMID 16816213 DOI: 10.1176/Appi.Ajp.163.7.1132  1
2006 Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 51: 382-6. PMID 16786820 DOI: 10.1177/070674370605100608  1
2006 Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood Schizophrenia Research. 85: 222-231. PMID 16679001 DOI: 10.1016/J.Schres.2006.03.033  1
2006 Remington G, Saha A, Chong SA, Shammi C. Augmenting strategies in clozapine-resistant schizophrenia Cns Drugs. 20: 171. PMID 16478292 DOI: 10.2165/00023210-200620020-00008  1
2006 Faulkner G, Cohn T, Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia Schizophrenia Research. 82: 225-231. PMID 16360305 DOI: 10.1016/J.Schres.2005.10.020  1
2005 Remington G, Kapur S, Andreasen NC. Remission: What's in a name? [4] (multiple letters) American Journal of Psychiatry. 162: 2393-2394. PMID 16330612 DOI: 10.1176/Appi.Ajp.162.12.2393-A  1
2005 Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia Cns Drugs. 19: 843-872. PMID 16185094 DOI: 10.2165/00023210-200519100-00004  1
2005 Potkin SG, Gharabawi GM, Greenspan AJ, Rupnow MF, Kosik-Gonzalez C, Remington G, Ruetsch C, Revicki D. Psychometric evaluation of the Readiness for Discharge Questionnaire. Schizophrenia Research. 80: 203-12. PMID 16102943 DOI: 10.1016/J.Schres.2005.06.021  1
2005 Remington G, Shammi C, Brown PC, Tucker WM. Overstating the case about recovery? [1] (multiple letters) Psychiatric Services. 56: 1022-1023. PMID 16088024 DOI: 10.1176/Appi.Ps.56.8.1022  1
2005 Remington G. Rational pharmacotherapy in early psychosis British Journal of Psychiatry. 187. PMID 16055813 DOI: 10.1192/bjp.187.48.s77  1
2005 Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? Schizophrenia Research. 76: 267-72. PMID 15949658 DOI: 10.1016/J.Schres.2005.01.009  1
2005 Chung C, Remington G. Predictors and markers of clozapine response Psychopharmacology. 179: 317-335. PMID 15717209 DOI: 10.1007/S00213-005-2174-X  1
2005 Turrone P, Remington G, Kapur S, Nobrega JN. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biological Psychiatry. 57: 406-11. PMID 15705357 DOI: 10.1016/J.Biopsych.2004.10.023  1
2004 Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 49: 753-60. PMID 15633853 DOI: 10.1177/070674370404901106  1
2004 Remington G, Shammi C. The use of pharmacotherapy in the prodrome of schizophrenia Cns Spectrums. 9: 579-586. PMID 15273650 DOI: 10.1017/S1092852900002741  1
2004 Chong SA, Mythily, Remington G. Tardive Dyskinesia and Iron Status [5] Journal of Clinical Psychopharmacology. 24: 235-236. PMID 15206676 DOI: 10.1097/01.Jcp.0000117432.83724.6B  1
2004 Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. The American Journal of Psychiatry. 161: 818-25. PMID 15121646 DOI: 10.1176/Appi.Ajp.161.5.818  1
2004 Chue P, Stip E, Remington G, Kopala L. Switching atypical antipsychotics: A review Acta Neuropsychiatrica. 16: 301-313. DOI: 10.1111/J.0924-2708.2004.00098.X  1
2004 Kapur S, Sridhar N, Remington G. The newer antipsychotics: Underlying mechanisms and the new clinical realities Current Opinion in Psychiatry. 17: 115-121. DOI: 10.1097/00001504-200403000-00008  1
2004 Faulkner G, Cohn T, Remington G. Interventions to control weight gain in schizophrenia Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.Cd005148  1
2003 Jensen J, McIntosh AR, Crawley AP, Mikulis DJ, Remington G, Kapur S. Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron. 40: 1251-7. PMID 14687557 DOI: 10.1016/S0896-6273(03)00724-4  1
2003 Remington G. Understanding antipsychotic "atypicality": A clinical and pharmacological moving target Journal of Psychiatry and Neuroscience. 28: 275-284. PMID 12921222  1
2003 Stip E, Remington GJ, Dursun SM, Reiss JP, Rotstein E, MacEwan GW, Chokka PR, Jones B, Dickson RA. A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. Journal of Clinical Psychopharmacology. 23: 400-4. PMID 12920417 DOI: 10.1097/01.Jcp.0000085414.08426.8F  1
2003 Kiang M, Christensen BK, Remington G, Kapur S. Apathy in schizophrenia: Clinical correlates and association with functional outcome Schizophrenia Research. 63: 79-88. PMID 12892861 DOI: 10.1016/S0920-9964(02)00433-4  1
2003 Turrone P, Remington G, Kapur S, Nobrega JN. Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 1433-9. PMID 12838271 DOI: 10.1038/Sj.Npp.1300233  1
2003 Turrone P, Remington G, Kapur S, Nobrega JN. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology. 165: 166-71. PMID 12417967 DOI: 10.1007/S00213-002-1259-Z  1
2003 Chong SA, Mythily, Remington G. Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia Schizophrenia Research. 59: 67-71. PMID 12413644 DOI: 10.1016/S0920-9964(02)00156-1  1
2002 Dewa CS, Remington G, Herrmann N, Fearnley J, Goering P. How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clinical Therapeutics. 24: 1466-76. PMID 12380638 DOI: 10.1016/S0149-2918(02)80050-9  1
2002 Turrone P, Remington G, Nobrega JN. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neuroscience and Biobehavioral Reviews. 26: 361-80. PMID 12034136 DOI: 10.1016/S0149-7634(02)00008-8  1
2002 Cohn TA, Remington G, Kameh H. Hyperinsulinemia in psychiatric patients treated with olanzapine [2] Journal of Clinical Psychiatry. 63: 75-76. PMID 11838632 DOI: 10.4088/Jcp.V63N0114B  1
2002 Koren G, Cohn T, Chitayat D, Kapur B, Remington G, Reid DM, Zipursky RB. Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. The American Journal of Psychiatry. 159: 136-7. PMID 11772703 DOI: 10.1176/Appi.Ajp.159.1.136  1
2002 Remington G. 'Atypical' antipsychotics: Where does ziprasidone fit? Expert Review of Neurotherapeutics. 2: 13-24. DOI: 10.1586/14737175.2.1.13  1
2002 Remington G, Kapur S. Review: Amisulpride is effective and safe for schizophrenia - Commentary Evidence-Based Mental Health. 5: 85. DOI: 10.1136/Ebmh.5.3.85  1
2002 Sloman L, Konstantareas M, Remington G. Reply to Dr. King and Associates Journal of Clinical Psychopharmacology. 22: 526. DOI: 10.1097/00004714-200210000-00016  0.01
2002 Castro NS, Remington G. Performance evaluation of a reciprocating chiller using experimental data and model predictions for fault detection and diagnosis Ashrae Transactions. 108: 889-903.  1
2001 Remington G, Kapur S. SB-277011 GlaxoSmithKline Current Opinion in Investigational Drugs. 2: 946-949. PMID 11757796  1
2001 Kapur S, Remington G. Dopamine D2 receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient Biological Psychiatry. 50: 873-883. PMID 11743942 DOI: 10.1016/S0006-3223(01)01251-3  1
2001 Parker V, Remington G. Electroconvulsive therapy in cases of treatment-resistant psychosis [4] Canadian Journal of Psychiatry. 46: 762-763. PMID 11692983 DOI: 10.1177/070674370104600817  1
2001 Azorin JM, Spiegel R, Remington G, Vanelle JM, Péré JJ, Giguere M, Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. The American Journal of Psychiatry. 158: 1305-13. PMID 11481167 DOI: 10.1176/Appi.Ajp.158.8.1305  0.01
2001 Remington G, Khramov I. Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics Progress in Neuro-Psychopharmacology and Biological Psychiatry. 25: 363-369. PMID 11294482 DOI: 10.1016/S0278-5846(00)00167-6  1
2001 Chong SA, Remington G, Mahendran R, Chua HC. Awareness of tardive dyskinesia in Asian patients with schizophrenia. Journal of Clinical Psychopharmacology. 21: 235-7. PMID 11270922 DOI: 10.1097/00004714-200104000-00017  1
2001 Kapur S, Remington G. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia Annual Review of Medicine. 52: 503-517. PMID 11160792 DOI: 10.1146/Annurev.Med.52.1.503  1
2001 Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. The American Journal of Psychiatry. 158: 311-4. PMID 11156818 DOI: 10.1176/Appi.Ajp.158.2.311  1
2001 Remington G, Shammi CM, Sethana R, Lawrence R. Antipsychotic dosing patterns for schizophrenia in three treatment settings Psychiatric Services. 52: 96-98. PMID 11141536 DOI: 10.1176/Appi.Ps.52.1.96  1
2001 Remington G. Psychopharmacology of Antipsychotics Psychopharmacology of Antidepressants American Journal of Psychiatry. 158: 1538-1538. DOI: 10.1176/Appi.Ajp.158.9.1538  0.01
2001 Remington G. Intramuscular ziprasidone reduced symptoms and was well tolerated in acute psychosis: Commentary Evidence-Based Mental Health. 4: 74. DOI: 10.1136/Ebmh.4.3.74  1
2000 Chong SA, Remington G. Clozapine augmentation: Safety and efficacy Schizophrenia Bulletin. 26: 421-440. PMID 10885641  1
2000 Kapur S, Wadenberg ML, Remington G. Are animal studies of antipsychotics appropriately dosed?: Lessons from the bedside to the bench Canadian Journal of Psychiatry. 45: 241-246. PMID 10779880 DOI: 10.1177/070674370004500302  1
2000 Remington G. Schizophrenia: Building and fixing scientific models Canadian Journal of Psychiatry. 45: 239-240. PMID 10779879  1
2000 Remington G, Kapur S. Atypical antipsychotics: Are some more atypical than others? Psychopharmacology. 148: 3-15. PMID 10663410  1
2000 Remington G. Review: Zotepine was as effective as typical and other atypical antipsychotics and more effective than placebo in schizophrenia: Commentary Evidence-Based Mental Health. 3: 78. DOI: 10.1136/Ebmh.3.3.78  1
1999 Remington G, Chong SA. Conventional versus novel antipsychotics: Changing concepts and clinical implications Journal of Psychiatry and Neuroscience. 24: 431-441. PMID 10586534  1
1999 Chong SA, Remington G, Tan CH. Risperidone treatment of tardive dyskinesia and dystonia [6] Journal of Clinical Psychiatry. 60: 340-341. PMID 10362448 DOI: 10.4088/Jcp.V60N0512I  1
1999 Remington G, Chong SA, Kapur S. Distinguishing change in primary and secondary negative symptoms [12] American Journal of Psychiatry. 156: 974-975. PMID 10360154 DOI: 10.1176/Ajp.156.6.974  1
1999 Remington G, Kapur S. D2 and 5-HT2 receptor effects of antipsychotics: Bridging basic and clinical findings using PET Journal of Clinical Psychiatry. 60: 15-19. PMID 10340683  1
1999 Chong SA, Remington G, Perry PJ, Sanger T, Beasley CM. Plasma olanzapine and clinical response [9] (multiple letters) Journal of Clinical Psychopharmacology. 19: 192-193. PMID 10211929 DOI: 10.1097/00004714-199904000-00023  1
1999 Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia American Journal of Psychiatry. 156: 286-293. PMID 9989565 DOI: 10.1176/Ajp.156.2.286  1
1998 Chong SA, Remington G. Re: Sertraline-clozapine interaction [6] Canadian Journal of Psychiatry. 43: 856-857. PMID 9806097  1
1998 Remington G, Kapur S, Zipursky RB. Pharmacotherapy of first-episode schizophrenia British Journal of Psychiatry. 172: 66-70. PMID 9764129 DOI: 10.1192/S0007125000297687  1
1998 Kapur S, Zipursky RB, Remington G, Meltzer H. Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and serotonin2 receptor occupancy [3] (multiple letters) Archives of General Psychiatry. 55: 666-668. PMID 9672060 DOI: 10.1001/Archpsyc.55.7.666  1
1998 Chong SA, Remington G. Ethnicity and clozapine metabolism British Journal of Psychiatry. 172: 97. PMID 9534846  1
1998 Remington G, Kapur S, Zipursky R. The relationship between risperidone plasma levels and dopamine D2 occupancy: A positron emission tomographic study [1] Journal of Clinical Psychopharmacology. 18: 82-83. PMID 9472848 DOI: 10.1097/00004714-199802000-00014  1
1998 Primeau FJ, Remington G. Evidence through Clinical Experience with Novel Antipsychotics The Canadian Journal of Psychiatry. 43. DOI: 10.1177/07067437980430S101  0.01
1998 Chong SA, Remington G. RE: Hypertension and increased serum clozapine association with clozapine and fluoxetine in combination [5] Irish Journal of Psychological Medicine. 15: 112.  1
1997 Collins AA, Remington GJ, Coulter K, Birkett K. Insight, neurocognitive function and symptom clusters in chronic schizophrenia Schizophrenia Research. 27: 37-44. PMID 9373893 DOI: 10.1016/S0920-9964(97)00075-3  1
1997 Shammi CM, Remington G. Clozapine-induced necrotizing colitis [8] Journal of Clinical Psychopharmacology. 17: 230-232. PMID 9169975 DOI: 10.1097/00004714-199706000-00021  1
1997 Remington G. Book Review: Schizophrenia: Critical Issues in the Treatment of SchizophreniaCritical Issues in the Treatment of Schizophrenia. BrunelloN, RacagniG, LangerSZ, MendlewiczJ, editors. Basel: Karger; 1995. 205 p. US$198.25. The Canadian Journal of Psychiatry. 42: 876-876. DOI: 10.1177/070674379704200812  0.01
1996 Iruela LM, Remington G, Adams M. Risperidone and obsessive-compulsive symptoms [7] Journal of Clinical Psychopharmacology. 16: 85-86. PMID 8834429  1
1996 Collins AA, Remington G, Coulter K, Birkett K. Depression in schizophrenia: A comparison of three measures Schizophrenia Research. 20: 205-209. PMID 8794511 DOI: 10.1016/0920-9964(95)00107-7  1
1996 Remington GJ, Addington D, Collins EJ, Jones BD, Lalonde P, MacCrimmon DJ, MacEwan GW. Clozapine: current status and role in the pharmacotherapy of schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 41: 161-6. PMID 8722645 DOI: 10.1177/070674379604100306  1
1996 Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia American Journal of Psychiatry. 153: 466-476. PMID 8599393 DOI: 10.1176/Ajp.153.4.466  1
1996 Remington G, Bezchlibnyk-Butler K. Management of acute antipsychotic-induced extrapyramidal syndromes Cns Drugs. 5: 21-35. DOI: 10.2165/00023210-199600051-00005  1
1996 Remington G, Adams M. Reply: Risperidone and Obsessive-Compulsive Symptoms Journal of Clinical Psychopharmacology. 16: 85-86. DOI: 10.1097/00004714-199602000-00020  1
1995 Remington G. Understanding schizophrenia: The impact of novel antipsychotics Canadian Journal of Psychiatry. 40. PMID 8564914 DOI: 10.1177/070674379504007S01  1
1995 Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 40: S5-11. PMID 7627927  1
1995 Remington GJ. The long-term treatment of schizophrenia Canadian Journal of Psychiatry. 40. PMID 7627926  1
1995 Remington GJ. Love without romance: The complexity of erotomanic delusions [2] Journal of Clinical Psychiatry. 56: 533-534. PMID 7592509  1
1994 Remington GJ, Jeffries JJ. Erotomanic delusions and electroconvulsive therapy: A case series Journal of Clinical Psychiatry. 55: 306-308. PMID 8071292  1
1994 Bezchlibnyk-Butler KZ, Remington GJ. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms Canadian Journal of Psychiatry. 39: 74-84. PMID 7908605  1
1994 Remington GJ. Novel neuroleptics in schizophrenia: Theory and clinical relevance Canadian Journal of Psychiatry. 39. PMID 7533050  1
1994 Remington G, Adams M. Risperidone and obsessive-compulsive symptoms Journal of Clinical Psychopharmacology. 14: 358-359. PMID 7528755 DOI: 10.1097/00004714-199410000-00014  1
1993 Baskys A, Wang S, Remington G, Martin Wojtowicz J. Haloperidol and loxapine but not clozapine increase synaptic responses in the hippocampus European Journal of Pharmacology. 235: 305-307. PMID 8508910 DOI: 10.1016/0014-2999(93)90151-7  1
1993 Remington G, Pollock B, Voineskos G, Reed K, Coulter K. Acutely psychotic patients receiving high-dose haloperidol therapy Journal of Clinical Psychopharmacology. 13: 41-45. PMID 8486816 DOI: 10.1097/00004714-199302000-00005  1
1993 Remington G, Fornazzari L, Sethna R. Placebo response in refractory tardive akathisia Canadian Journal of Psychiatry. 38: 248-250. PMID 8100184 DOI: 10.1177/070674379303800404  1
1993 Remington GJ. Clinical considerations in the use of risperidone Canadian Journal of Psychiatry. 38. PMID 7504575  1
1993 Remington GJ, Book H. Discriminative validity of the borderline syndrome index Journal of Personality Disorders. 7: 312-319.  1
1992 Jeffries J, Bezchlibnyk-Butler K, Remington G. Amenorrhea and galactorrhea associated with fluvoxamine in a loxapine-treated patient Journal of Clinical Psychopharmacology. 12: 296-297. PMID 1527236 DOI: 10.1097/00004714-199208000-00024  1
1991 Fornazzari L, Remington G, Jeffries J. Akathisia, porphyria and low iron [1] Canadian Journal of Psychiatry. 36: 548. PMID 1933767 DOI: 10.1177/070674379103600722  1
1991 Cheung SW, Tang SW, Remington G. Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography Journal of Chromatography B: Biomedical Sciences and Applications. 564: 213-221. PMID 1860915 DOI: 10.1016/0378-4347(91)80083-O  1
1991 Fornazzari L, Ichise M, Remington G, Smith I. Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings Journal of Psychiatry and Neuroscience. 16: 227-229. PMID 1786266  1
1991 Remington GJ, Rosenblat H. Spousal allegations of incest during transient psychotic episodes British Journal of Psychiatry. 159: 287-288. PMID 1773251  1
1990 Remington G, Menuck M, Schmidt P, Legault S. The remitting atypical psychoses: clinical and nosologic considerations Canadian Journal of Psychiatry. 35: 36. PMID 2317732 DOI: 10.1177/070674379003500106  1
1990 Tang SW, Remington G, Persad E, Rosenblat R. Coadministration of a beta-adrenergic antagonist and a tricyclic antidepressant: A pilot study Psychiatry Research. 33: 101-106. PMID 2243886 DOI: 10.1016/0165-1781(90)90062-A  1
1990 Remington GJ, Voineskos G, Pollock B, Reed K, Coulter K. Prevalence of neuroleptic-induced dystonia in mania and schizophrenia American Journal of Psychiatry. 147: 1231-1233. PMID 1974747 DOI: 10.1176/ajp.147.9.1231  1
1990 Remington G. Free radicals and tardive dyskinesia (I:Reply) Canadian Journal of Psychiatry. 35: 283-284.  1
1989 Remington GJ. Sexual life events and schizophrenia Comprehensive Psychiatry. 30: 114. PMID 2924562  1
1989 Remington G, DaCosta G. Ethnocultural factors in resident supervision: Black supervisor and white supervisees American Journal of Psychotherapy. 43: 398-404. PMID 2817150  1
1989 Menuck M, Legault S, Schmidt P, Remington G. The nosologic status of the remitting atypical psychoses Comprehensive Psychiatry. 30: 53-73. PMID 2647402 DOI: 10.1016/0010-440X(89)90118-1  1
1989 Remington G. Pharmacotherapy of schizophrenia Canadian Journal of Psychiatry. 34: 211-220. PMID 2566367  1
1989 Remington GJ. Correspondence Comprehensive Psychiatry. 30: 114. DOI: 10.1016/0010-440X(89)90126-0  1
1988 Remington GJ. The pisa syndrome: Possible role for serotonin and noradrenaline Journal of Clinical Psychopharmacology. 8: 228-229. PMID 2897980  1
1984 Remington G, Jeffries JJ. The role of cerebral arteriovenous malformations in psychiatric disturbances: Case report Journal of Clinical Psychiatry. 45: 226-229. PMID 6725213  1
1984 Remington G, Hoffman BF. Gas sniffing as a form of substance abuse Canadian Journal of Psychiatry. 29: 31-35. PMID 6704883 DOI: 10.1177/070674378402900107  1
1984 Remington G, Book H. Case report of de Clerembault syndrome, bipolar affective disorder, and response to lithium American Journal of Psychiatry. 141: 1285-1287. PMID 6486270  1
1984 Jeffries J, Remington G, Wilkins J. The question of lithium/neuroleptic toxicity Canadian Journal of Psychiatry. 29: 601-604. PMID 6150756 DOI: 10.1177/070674378402900711  1
1979 Anisman H, Remington G, Sklar LS. Effect of inescapable shock on subsequent escape performance: catecholaminergic and cholinergic mediation of response initiation and maintenance. Psychopharmacology. 61: 107-24. PMID 108728 DOI: 10.1007/BF00426724  1
1978 Anisman H, DeCatanzaro D, Remington G. Escape performance following exposure to inescapable shock: Deficits in motor response maintenance Journal of Experimental Psychology: Animal Behavior Processes. 4: 197-218. DOI: 10.1037/0097-7403.4.3.197  1
1976 Anisman H, Kokkinidis L, Glazier S, Remington G. Differentiation of response biases elicited by scopolamine and d-amphetamine: effects on habituation. Behavioral Biology. 18: 401-17. PMID 1016178 DOI: 10.1016/S0091-6773(76)92407-X  1
1976 Remington G, Anisman H. Genetic and ontogenetic variations in locomotor activity following treatment with scopolamine or d amphetamine Developmental Psychobiology. 9: 579-585. PMID 1001843 DOI: 10.1002/Dev.420090611  1
1976 Remington G, Anisman H. A simple method for quantifying tremor in rodents Pharmacology, Biochemistry and Behavior. 4: 721-723. PMID 981289 DOI: 10.1016/0091-3057(76)90226-4  1
1974 Remington G, Anisman H. Disruptive effects of epinephrine on active avoidance behavior: Alteration by scopolamine and d-amphetamine Pharmacology, Biochemistry and Behavior. 2: 427-430. PMID 4837911 DOI: 10.1016/0091-3057(74)90092-6  1
1949 Remington GE. Nathaniel Remington Notes and Queries. 194: 572. DOI: 10.1093/nq/194.26.572-a  1
1936 Remington GC. Purposes of the Institute of Public Administration Public Administration. 14: 30-39. DOI: 10.1111/j.1467-9299.1936.tb02415.x  1
Show low-probability matches.